Clinical guidelines are being made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Clinical Practice Guideline Web page to determine the date of the most recent update to this document: www.bop.gov/resources/health_care_mngmt.jsp#cpg.
What’s New in This Document?

The following changes have been made since the June 2011 version of these guidelines. Where appropriate, the changes are highlighted in yellow. Please note that the guidelines are now entitled, Management of HIV Infection.

Medical Evaluation

- Newly diagnosed patients should be asked about any prior use of antiretroviral agents for prevention of HIV infection.

- Table 5, Recommended Laboratory Studies for Patients Presenting with HIV Infection, has been updated.

- Under Immunization Status, information regarding the pneumococcal vaccine has been added.

- Dental evaluations could be the first presentation of HIV symptoms. See the new section on Dental Management, which includes additional dental resources as footnote references, and Table 8, which summarizes dental management practices based on CD4 cells/mm$^3$.

Testing and Treatment

- Wording has been added to clarify the policies for voluntary testing, under Indications for Testing for HIV and in Appendix 2.

- Treatment information was updated to be in line with the February 12, 2013, DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. (See link to the DHHS guidelines in Appendix 1.) Please note the highlighted treatment information throughout Section 8 and in the relevant Appendices.

- Updated guidance for dental considerations in the co-management of oral conditions

New Appendix

- HIV drug-resistance testing is recommended for persons with HIV infection when they enter into care, and genotypic testing is the preferred resistance testing to guide therapy in ARV-naive patients. The new Appendix 12, Recommendations for Using Drug-Resistance Assays, is based on the updated DHHS guidelines mentioned above.

The June 2011 version of these guidelines contained the following changes to June 2006 version:

General

- Tables of antiretroviral drugs are no longer included because they rapidly become outdated. Clinicians should routinely review updated Department of Health and Human Services (DHHS) guidelines at http://www.aidsinfo.nih.gov/guidelines/.


Nomenclature

- Pneumocystis jiroveci (pronounced “yee row vet zee”) is the correct name for what was previously Pneumocystis carinii. PCP remains an appropriate abbreviation for pneumocystis pneumonia.

Treatment

- Treatment information was updated to be in line with the January 10, 2011, DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.

- A section was added on Management of the Treatment-Experienced Patient.

- The immunization recommendations were updated.

New Appendices

- A new appendix was inserted: Appendix 7, DHHS Antiretroviral Guidelines: Rating Scheme and Acronyms.

- The procedure to follow when doing Pap smears is outlined in Appendix 11 for easy access.
# Table of Contents

1. **Purpose and Overview** .................................................. 1  
2. **Diagnosis and Reporting** ............................................... 1  
   - Indications for Testing for HIV ........................................ 1  
   - Indications for Testing for HIV-2 .................................... 2  
   - HIV Prevention Counseling ............................................... 2  
   - Antibody Testing and Interpretation of Results .................... 2  
   - Acute HIV Infection ...................................................... 4  
   - Reporting .................................................................. 4  
3. **Natural History of HIV Infection** ..................................... 4  
4. **Baseline Medical Evaluation** .......................................... 5  
   - History and Physical Examination ..................................... 5  
   - Laboratory Tests .......................................................... 6  
   - Immunization Status ...................................................... 8  
   - Referrals and Treatment Plan ............................................ 8  
5. **Classification of HIV Infection** ....................................... 8  
6. **Periodic Medical Evaluations** .......................................... 9  
   - History and Physical Examination/Laboratory Monitoring ....... 9  
   - Immunologic/Virologic Monitoring ...................................... 9  
   - Laboratory and Diagnostic Studies ................................... 9  
7. **Prophylaxis for Opportunistic Infections (OIs)** ................... 10  
   - Indications and Prophylaxis Regimens ............................... 10  
   - Discontinuation of OI Prophylaxis ..................................... 11  
   - Treatment of Opportunistic Infections ............................... 12  
8. **Treatment: Antiretroviral Therapy (ART)** ......................... 13  
   8a. Treatment Goals ....................................................... 13  
   8b. Initiating Antiretroviral Therapy in Treatment-Naïve Patients ... 13  
      - Use of CD4 Counts for Initial Assessment ......................... 13  
      - Viral Load Testing ...................................................... 13  
      - HIV Drug-Resistance Testing ....................................... 14  
      - Recommendations for Initiating Therapy ....................... 14  
      - Adherence Considerations .......................................... 15  
   8c. What to Start: Initial Combination Regimens for the Antiretroviral-Naïve Patient ... 16  
      - Preferred Regimens ...................................................... 16  
      - Alternative Regimens ................................................... 17  
      - Comparison of Preferred Regimens ................................ 18  
      - Immune Reconstitution ............................................... 19  
   8d. Management of the Treatment-Experienced Patient ............... 19  
      - Virologic and Immunologic Definitions ............................. 19  
      - Assessment of Virologic Failure ................................... 19  
      - Changing ART .......................................................... 20  
      - Management of Virologic Failure ................................... 20  
   8e. Regimen Simplification .................................................. 21
Appendices

Appendix 1. Guidelines Regarding Medical Care of HIV-Infected Persons ............................................. 34
Appendix 2. Criteria for Testing for HIV Infection .................................................................................... 35
Appendix 3. Correlation of Complications with CD4+ T Cell Count ....................................................... 36
Appendix 4. Baseline and Periodic Medical/Laboratory Evaluations for Inmates with HIV Infection .. 37
Appendix 5. HIV Classification System ..................................................................................................... 38
Appendix 6. Prophylaxis for HIV-Related Opportunistic Infections ...................................................... 39
Appendix 7. DHHS Antiretroviral Guidelines: Rating Scheme and Acronyms ........................................... 40
Appendix 8. Initiating Antiretroviral Therapy in Treatment-Naïve Patients ............................................. 41
Appendix 9. Preferred Treatment Regimens for Antiretroviral-Naïve Patients ....................................... 42
Appendix 10. Antiretroviral Drugs and Components NOT Recommended .............................................. 43
Appendix 11. Procedure for Pap Smears .................................................................................................... 45
Appendix 12. Recommendations for Using Drug-Resistance Assays ...................................................... 46
1. Purpose and Overview

The BOP Clinical Practice Guidelines for the Management of HIV Infection provide guidance on the screening, evaluation, and treatment of federal inmates with HIV infection, with a focus on primary care. The BOP clinical practice guidelines are not intended to replace the more extensive guidelines published by the United States Public Health Services (USPHS), the Department of Health and Human Services (DHHS), the Centers for Disease Control and Prevention (CDC), the Infectious Disease Society of America (IDSA), and the International AIDS Society (IAS). See Appendix I, Guidelines Regarding Medical Care of HIV-Infected Persons, for a list of these guidelines and the links for internet access. The DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents are updated regularly and should be consulted at: http://www.aidsinfo.nih.gov/guidelines/.

2. Diagnosis and Reporting

Indications for Testing for HIV

- **Opt-out voluntary testing** is offered to all designated inmates after arrival to the designated institution.
- **Voluntary testing** is also done when the inmate requests testing via an Inmate Request to Staff Member (BP-S148) form, which will be turned into Health Services. This voluntary testing is available to all inmates regardless of sentencing or duration of stay.
- **Mandatory testing** is performed when there are indications/risk factors and the test is clinically indicated and/or surveillance testing is required. Inmates must participate in mandatory HIV testing programs.
- **Involuntary testing** is performed following an exposure incident. Written consent of the inmate is not required. If an inmate refuses testing, testing will be conducted in accordance with the Program Statement on Use of Force.

Indications for HIV testing are described in detail in Appendix 2, Criteria for Testing for HIV Infection, and summarized in Table 1 below.

| Test all inmates with the following, regardless of sentencing or duration of stay: |
| Signs or symptoms of acute HIV infection | Recent HIV exposure |
| Signs or symptoms of HIV-related condition | Active tuberculosis |
| Pregnancy | Or when otherwise clinically indicated |

| Criteria for mandatory HIV testing for sentenced (> 6 months) inmates with the following risk factors: |
| Injected illegal drugs and shared equipment | History of gonorrhea or syphilis |
| (For males) sex with another man | Received blood products between 1977 and 1985 |
| Had unprotected intercourse with a person with known or suspected HIV infection | Hemophilia |
| Unprotected intercourse with more than one sex partner | Percutaneous exposure to blood |
| From a high-risk country (sub-Saharan Africa or West Africa) | Positive tuberculin skin test |

| Voluntary HIV testing for all sentenced inmates: |
| **Opt-out voluntary testing** is offered to all designated inmates after arrival to the designated institution. Many persons with HIV infection are asymptomatic and are unaware of their infection; therefore, consistent with guidelines from the Centers for Disease Control and Prevention and the issued memorandum from the BOP Medical Director, **all sentenced inmates should universally be offered HIV testing at the time of incarceration.** |
| **Voluntary testing** via an Inmate Request to Staff Member (BP-S148) form is also available to all inmates regardless of sentencing or duration of stay. |
Indications for Testing for HIV-2

Any asymptomatic, sentenced inmates who meet the criteria listed below in Table 2 should also be tested for HIV-2 infection through BOP reference laboratories.

<table>
<thead>
<tr>
<th>Table 2. Criteria for Testing for HIV-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>• All inmates from West Africa where HIV-2 is endemic such as the countries of Benin, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone, Togo, Ghana, Burkina Faso, Gambia, and Côte d’Ivoire.</td>
</tr>
<tr>
<td>• Inmates who are or have been sex partners or needle-sharing partners of persons from West Africa or any person known to have HIV-2 infection.</td>
</tr>
<tr>
<td>• Inmates who have received transfusions in West Africa.</td>
</tr>
</tbody>
</table>

HIV Prevention Counseling

All inmates tested for HIV infection should receive counseling from qualified health care personnel in accordance with BOP policy, using the appropriate forms for HIV counseling and documentation. Counseling should provide information on:

• HIV transmission,
• Methods for preventing the spread of the virus while in prison and upon release to the community
• The importance of obtaining test results
• How to get the test results
• The meaning of the HIV test results

HIV prevention counseling should incorporate effective elements recommended by the CDC that include, but are not limited to: using open-ended questioning; carefully assessing personal risk, based on self-reported behaviors and the inmate’s medical evaluation; clarifying critical misconceptions; emphasizing risk reduction behaviors; and using clear and direct language when providing test results.

Antibody Testing and Interpretation of Results

Only FDA-approved HIV tests should be used for diagnostic purposes. The diagnosis of HIV infection is ordinarily determined by a screening immunoassay (EIA) or rapid HIV test followed by a confirmatory Western Blot (WB). Results of HIV WB are generally interpreted as outlined in Table 3 below. WB testing should always be coupled with EIA screening due to a 2% rate of false positives.

<table>
<thead>
<tr>
<th>Table 3. Interpretation of Western Blot Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
</tr>
<tr>
<td>Nonreactive (no bands on Western blot)</td>
</tr>
<tr>
<td>Positive</td>
</tr>
<tr>
<td>Reactivity to gp120/160 + either gp41 or p24</td>
</tr>
<tr>
<td>Indeterminate</td>
</tr>
<tr>
<td>Presence of any band patterns not meeting criteria for a positive result</td>
</tr>
</tbody>
</table>

False negative, false positive, and indeterminate results are uncommon. Reasons for such results are outlined in Table 4 below.
Table 4. Reasons for False Negative, False Positive, and Indeterminate HIV Test Results

<table>
<thead>
<tr>
<th>Reasons for False Negative Results:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recent acute HIV infection</strong></td>
</tr>
<tr>
<td>During the “window” period (i.e., the time between new infection and the development of HIV antibodies), HIV EIA tests may be negative. Some do not convert for 3 to 4 weeks. Nearly all infected persons develop HIV antibodies within 6 months of infection.</td>
</tr>
<tr>
<td><strong>Seroreversion</strong></td>
</tr>
<tr>
<td>Persons with documented HIV infection can lose HIV antibodies with late-stage disease (AIDS) or with immune reconstitution by effective antiretroviral therapy.</td>
</tr>
<tr>
<td><strong>Agammaglobulinemia</strong></td>
</tr>
<tr>
<td>Low antibodies (confirm with HIV viral load).</td>
</tr>
<tr>
<td><strong>HIV O and HIV N</strong></td>
</tr>
<tr>
<td>Standard EIA may be falsely negative in persons infected with HIV O subtype or HIV N subtype. O and N subtypes are extremely rare variants of HIV-1.</td>
</tr>
<tr>
<td><strong>HIV-2</strong></td>
</tr>
<tr>
<td>HIV-2 infection occurs primarily in West Africa. Standard HIV EIA tests are falsely negative in 20–30% of persons infected with HIV-2. Specific antibody tests for HIV-2 are available through the CDC via BOP reference laboratories.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reasons for False Positive Results:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Autoantibodies (extremely rare)</td>
</tr>
<tr>
<td>• Investigational HIV vaccines</td>
</tr>
<tr>
<td>• Clerical error</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reasons for Indeterminate Results:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(see also discussion that follows table)</td>
</tr>
<tr>
<td><strong>Recent HIV infection</strong></td>
</tr>
<tr>
<td>HIV antibodies differentially become detectable within weeks after infection. Anti-p24 is usually the first antibody to appear.</td>
</tr>
<tr>
<td><strong>Atypical HIV strains</strong></td>
</tr>
<tr>
<td>Infection with unusual strains of HIV such as HIV-2 infection, or HIV-1 subtypes O or N, may not produce typical diagnostic bands on Western blot analysis.</td>
</tr>
<tr>
<td><strong>Cross reactive antibodies</strong></td>
</tr>
<tr>
<td>Autoimmune diseases, certain malignancies, injection drug use, HIV vaccination, and recent immunization may yield antibodies that are detectable on HIV Western blot analysis.</td>
</tr>
<tr>
<td><strong>Advanced HIV infection</strong></td>
</tr>
<tr>
<td>Loss of HIV antibodies because of AIDS itself may affect Western blot analysis.</td>
</tr>
</tbody>
</table>


Inmates with indeterminate HIV test results should be referred to a physician for further evaluation as follows:

- **Physician interview** for HIV infection risk factors, symptoms of HIV infection and AIDS, and causes of indeterminate HIV test results.
- **Physician evaluation** of the inmate for conditions that may result in an indeterminate test result, when clinically indicated by the inmate’s history and examination.
- **Repeat HIV testing:** Indeterminate results can usually be evaluated through risk assessment and viral load measurement. Patients evaluated as low-risk are seldom infected with HIV and may continue to show indeterminate results. These patients
should be reassured that HIV infection is unlikely and should receive follow-up serology, to include viral load, at 3 months. Patients with risk factors, who are in the process of seroconversion, will usually have positive WBs within 1 month, as well as high viral loads. These patients should have repeat serology, to include viral load, in 1–2 months. Viral detection methods may be used as an adjunctive diagnostic tool, but should not supplant antibody testing.

Acute HIV Infection

Acute HIV Infection should be suspected in patients experiencing typical symptoms accompanied by high-risk exposure within the past 4 weeks. This diagnosis is supported by a high viral load (>10,000) accompanied by a negative or indeterminate serology. These patients should be counseled concerning the substantial risk of transmission during the acute phase of infection.

Reporting

All inmates diagnosed with HIV infection should be reported to state health authorities in accordance with state laws and regulations.

3. Natural History of HIV Infection

Acute HIV infection leads to marked HIV viremia, with a rapid decline in CD4+ T cells that is usually associated with significant symptomatology—most commonly fever, rash, lymphadenopathy, and fatigue. Acute HIV infection is frequently unsuspected by the evaluating clinician, since signs and symptoms are relatively nonspecific and may not be reported by the patient. Less common manifestations of acute HIV infection include candida, mucocutaneous ulcerations of the mouth and esophagus, diarrhea, aseptic meningitis, facial palsy, Guillain-Barre syndrome, and cognitive impairment.

The avid immune response following acute HIV infection is associated with HIV antibody development, an increase in CD4+ T cells, and a reduction in HIV viremia with the establishment of a viral load set point. Over time, the CD4+ T cell count gradually declines in persons chronically infected with HIV, whereas HIV RNA levels gradually increase.

In the absence of antiretroviral therapy, the average time from acute HIV infection to symptomatic HIV infection or AIDS is 8 years. AIDS is associated with marked immunosuppression with a CD4+ T cell count <200 cells/mm³, the development of opportunistic infections, neurologic complications, certain malignancies, and wasting syndrome.

Appendix 3 lists complications associated with declining CD4+ T cell counts.

Antiretroviral therapy markedly prolongs life and prevents the development of AIDS. Although antiretroviral therapy can suppress plasma HIV RNA to undetectable levels for years, treatment is not curative since reservoirs of HIV persist, particularly in latent CD4+ T cells. HIV-2 infection causes a cell-mediated immunodeficiency similar to HIV-1 infection; however, CD4+ T cells decline more slowly.
4. **Baseline Medical Evaluation**

The baseline medical evaluation that is indicated for inmates diagnosed with HIV infection ordinarily includes the following components, which are summarized in *Appendix 4*.

**History and Physical Examination**

**Medical history:** Obtain a comprehensive medical history, along with an assessment and documentation of HIV risk factors. The history should include the date when HIV infection was diagnosed and, when possible, the estimated date of infection (based on the history of prior negative results, the history of symptoms of acute retroviral infection, or the inmate’s recollection of high-risk activities). History of prior HIV-related complications should be ascertained, including opportunistic infections, malignancies, and HIV-related symptoms. If possible, prior medical records should be obtained.

**Medication history:** A thorough medication history is critical for patients with prior history of antiretroviral therapy; it should include antiretroviral (ARV) regimens prescribed, response to each regimen, drug toxicities, adherence, and prior resistance test results. Newly diagnosed patients should also be asked about any prior use of ARV agents for prevention of HIV infection.

**Complete physical examination:** The examination should include a fundoscopic examination for retinopathy, an oropharyngeal exam for *candida* and other significant oral manifestations, a careful skin exam for dermatologic conditions, an abdominal exam for hepatosplenomegaly, an assessment of neurologic deficits, and a pelvic examination and Pap smear for women. The incidence of cervical pathology is 10 to 11-fold greater in HIV-infected women than in HIV-uninfected women.

**Pap smears:** Obtain Pap smears in accordance with the procedure outlined in *Appendix 11*. Pap smear results should be interpreted in accordance with established guidelines as follows:

- **Inmates with evidence of severe inflammation** should be evaluated for infection and receive a repeat Pap smear in 3 months.
- **Inmates with Pap smears with cellular atypia or atypical squamous cells of uncertain significance (ASCUS)** should have follow-up Pap smears without colposcopy every 6 months for 2 years, until three Pap smears in a row are negative. If atypia is noted a second time, the inmate should be referred for colposcopy. HPV testing can also be performed in patients with ASCUS to identify HPV types 16, 18, 31, 33, or 35 that predispose to cervical cancer and warrant colposcopy.
- **Inmates with Pap smears with low-grade cervical intraepithelial neoplasia (CIN I)** require careful follow-up with repeat Pap smears every 6 months and referral for colposcopy if any repeat Pap smear is abnormal.
- **Inmates with high-grade cervical intraepithelial neoplasia (CIN II or III), also termed carcinoma in situ**, require colposcopy for potential biopsy and follow-up monitoring.
- **Inmates with invasive carcinoma** require immediate referral to a specialist for evaluation and treatment.

---

Laboratory Tests

The following laboratory tests, performed during the initial patient visit, are used to stage HIV disease and assist in the selection of antiretroviral drug regimens:

- HIV antibody testing (if prior documentation is not available or if HIV RNA is below the assay’s limit of detection).
- CD4 T-cell count.
- Plasma HIV RNA (viral load).
- Complete blood count, chemistry profile, transaminase levels, blood urea nitrogen (BUN) and creatinine, urinalysis, and serologies for hepatitis A, B, and C viruses.
- Fasting blood glucose and serum lipids.
- Genotypic resistance testing at entry into care, regardless of whether antiretroviral therapy (ART) will be initiated immediately. For patients who have HIV RNA levels <500–1,000 copies/mL, amplification of virus for resistance testing may not always be successful.

Additional tests, including, screening tests for sexually transmitted infections and tests for determining risk for opportunistic infections and need for prophylaxis, should also be performed.

- Complete lists of recommended laboratories studies are included in Table 5 on the next page.
- See also Appendix 4, Baseline and Periodic Medical/Laboratory Evaluations for Inmates with HIV Infection.
<table>
<thead>
<tr>
<th><strong>Test</strong></th>
<th><strong>Comment(s)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-disease tests:</td>
<td></td>
</tr>
<tr>
<td>- Serologic testing for HIV</td>
<td></td>
</tr>
<tr>
<td>- CD4 cell count and percentage</td>
<td></td>
</tr>
<tr>
<td>- Plasma HIV RNA level (viral load)</td>
<td>Commercially available HIV-1 RNA assays do not detect HIV-2 viral load.</td>
</tr>
<tr>
<td>- Coreceptor tropism assay</td>
<td>Recommended prior to prescribing a CCR5 entry inhibitor</td>
</tr>
<tr>
<td>- HIV resistance testing</td>
<td>Genotype determination is preferred in antiretroviral-naïve patients</td>
</tr>
<tr>
<td>- HLA B*5701</td>
<td>Recommend prior to prescribing abacavir</td>
</tr>
<tr>
<td>Safety laboratory tests:</td>
<td></td>
</tr>
<tr>
<td>- Complete blood cell count with differential</td>
<td>Screen for deficiency in appropriate racial or ethnic groups</td>
</tr>
<tr>
<td>- Fasting lipid profile</td>
<td></td>
</tr>
<tr>
<td>- Glucose-6-phosphate dehydrogenase</td>
<td></td>
</tr>
<tr>
<td>- Serum chemistry</td>
<td></td>
</tr>
<tr>
<td>- Alanine aminotransferase, aspartate aminotransferase, bilirubin levels</td>
<td></td>
</tr>
<tr>
<td>- Albumin level</td>
<td></td>
</tr>
<tr>
<td>- Alkaline phosphatase level</td>
<td></td>
</tr>
<tr>
<td>- Electrolytes, blood urea nitrogen, creatinine levels</td>
<td></td>
</tr>
<tr>
<td>- Fasting blood glucose level or hemoglobin A1C</td>
<td></td>
</tr>
<tr>
<td>- Urinalysis: RBC, WBC, proteinuria, sediment levels</td>
<td></td>
</tr>
<tr>
<td>Co-infection and co-morbidity laboratory tests (tuberculosis)</td>
<td>All HIV-infected patients should be tested for <em>M. tuberculosis</em> infection by TST upon initiation of care. For an HIV-infected person, induration of &gt;5 mm is considered to be a positive result and should prompt chest radiography and other evaluation, as warranted, to rule out active tuberculosis.</td>
</tr>
<tr>
<td>Chest radiography</td>
<td>For patients with positive tuberculosis test result; consider in patients with underlying lung disease for use as comparison in evaluation of future respiratory illness.</td>
</tr>
<tr>
<td>Cytology: Pap test</td>
<td>Cytology; Pap test cervical.</td>
</tr>
<tr>
<td>Screening for syphilis (VDRL, RPR)</td>
<td>Confirm positives with FTA-ABS, MHA-TP, TPPA.</td>
</tr>
<tr>
<td>Screening for other STDs</td>
<td>Gonorrea/C. <em>trachomatis</em> in sexually active patients.</td>
</tr>
<tr>
<td>Serologic testing for <em>Toxoplasma gondii</em></td>
<td>All HIV-infected patients should be tested for prior exposure to <em>T. gondii</em> by measuring anti-<em>Toxoplasma</em> immunoglobulin (Ig) G upon initiation of care.</td>
</tr>
<tr>
<td>Viral hepatitis screening</td>
<td>Hepatitis B surface antigen, antibody to hepatitis B surface antigen or to hepatitis B core antigen, antibody to hepatitis C virus, total hepatitis A antibody.</td>
</tr>
</tbody>
</table>

**Note:**  
*RBC* = red blood cell, *STD* = sexually transmitted disease, *WBC* = white blood cell.
Immunization Status

**Recommended for All HIV Positive Adults**

- **Hepatitis B vaccine**: Recommended unless there is evidence of immunity or active hepatitis. Blood test to check for HBV antibody levels should be done after completion of immunization series. Additional shots may be necessary if antibody levels are too low.

- **Influenza vaccine**: Must be given every year. Only injectable flu vaccine should be given to those who are HIV positive. *The nasal spray vaccine (FluMist/LAIV) should not be used in this population.*

- **Pneumococcal vaccine**: Should be given soon after HIV diagnosis, unless vaccinated within the previous 5 years. Pneumococcal vaccine-naive persons should receive a dose of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13) first, followed by a dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23) at least 8 weeks later. Patients having received previous vaccination(s) with PPSV23 should be given a PCV13 dose ≥1 year after the last PPSV23 dose was received. A second PPSV23 is recommended 5 years after the first dose of PPSV23 for patients <65 years. Patients who received PPSV23 before age 65 should receive another dose at age 65 or later if at least 5 years have elapsed since their previous PPSV23 dose. For those patients who require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years after the most recent dose of PPSV23. If CD4 count is <200 cells/mm³ when the vaccine is given, immunization should be repeated when CD4 count is >200 cells/mm³. *(Source: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm)*

- **Tetanus and Diphtheria Toxoid (Td)**: Repeat every 10 years.

- **Tetanus, Diphtheria, and Pertussis (Tdap)**: Recommended for adults 64 years of age or younger and should be given in place of next Td booster.

**Recommended for Some HIV Positive Adults**


Referrals and Treatment Plan

All inmates receiving a baseline evaluation for HIV infection should have a treatment plan that is developed by the evaluating clinician and approved by a physician. Subspecialty referrals should be initiated as medically necessary and should include:

- **Referral for examination by a dentist** for all HIV-infected inmates.

- **Psychology referral, if clinically indicated** (in addition to the mandatory referral made as part of post-test counseling, in accordance with BOP policy).

5. **Classification of HIV Infection**

- All inmates diagnosed with HIV infection should be classified in accordance with the CDC classification system as outlined in [Appendix 5](#). HIV risk factors and classification should be documented appropriately. An inmate’s reclassification, and updated documentation of the reclassification, are indicated only when the inmate progresses to a more advanced stage of HIV infection, not during each evaluation or with clinical improvement.
6. Periodic Medical Evaluations

Periodic medical evaluations of inmates with HIV infection should include patient history, a physical examination, immunological monitoring, and laboratory and diagnostic studies—all briefly described below.

History and Physical Examination/Laboratory Monitoring

The frequency of the clinician’s physical examinations of an inmate with HIV infection should be based on the inmate’s immune status and other relevant clinical factors, as determined by the inmate’s physician. Medically complex inmates and inmates with AIDS should be followed closely by a physician.

- General guidelines regarding periodic medical evaluations are provided in Appendix 4.
  - Patient interviews and physical examinations should target the diagnosis of complications of HIV infection, consistent with the inmate’s stage of disease (see Appendix 3).
  - Dental referrals for co-management should continue with any new oral manifestation.

Immunologic/Virologic Monitoring

The inmate’s immunologic/virologic status should be monitored by the measurement of CD4+ T cell counts and plasma HIV RNA levels respectively, using FDA-approved testing methods.

- General guidelines for routine CD4+ T cell counts and HIV plasma RNA testing are provided in Appendix 4; the frequency of testing should be determined on an individual basis.

The indications and frequency of other laboratory monitoring depend on the inmate’s antiretroviral treatment regimen and prophylactic regimen for opportunistic infections.

Laboratory and Diagnostic Studies

The following additional studies should be considered during periodic evaluations of inmates with HIV infection:

- **Tuberculin skin tests (TST):** Annual TSTs are indicated for all inmates with prior TST measurements of <5 millimeters in duration. Inmates with HIV infection and a tuberculin skin test of 5 millimeters or greater are candidates for treatment of latent TB infection, presuming the evaluation for active TB disease is negative.

- **Periodic chest radiographs:** Periodic CXRs are required only for inmates with both HIV and latent TB coinfection who do not complete treatment of latent TB infection. In these cases, CXRs should be obtained semiannually for two years, and then continued semiannually only if the CD4+ T-cell count remains below 200/mm³.

- **Glucose-6-phosphate dehydrogenase (G-6-PD) testing:** Baseline G-6-PD testing is not routinely recommended for inmates with HIV infection. Prior to initiating a potentially offending agent, G-6-PD testing should be initiated on a case-by-case basis (considering both the patient’s risk for hemolytic anemia and the potential for serious complications from anemia). G-6-PD deficient inmates are susceptible to hemolytic anemia when exposed to oxidant drugs such as dapsone, primaquine, and, less
commonly, sulfonamides. African Americans and persons from Mediterranean countries, India, and Southeast Asia are most susceptible. Hemolysis is usually self-limited, involving only the older red blood cells. A small subset of Mediterraneans have a genetic variant that causes severe hemolysis when exposed to oxidant drugs. Affected patients present with severe fatigue, dyspnea, anemia, high bilirubin and LDH, reticulocytosis, methemoglobinemia, and bite cells on peripheral smear. During hemolysis, G-6-PD levels may be normal, despite an inherent deficiency, as susceptible cells are destroyed. Testing may not detect G-6-PD deficiency until 30 days after cessation of the offending drug.

- **Serum lipid analysis:** Inmates with cardiovascular risk factors or elevated baseline fasting triglyceride levels or LDL cholesterol levels should have lipid parameters monitored periodically while on antiretroviral therapy. The frequency of monitoring and the decision to medically intervene should be made on an individual basis, depending on the inmate’s medical history and the severity of any lipid abnormalities. More aggressive monitoring and treatment is indicated for inmates with multiple cardiovascular risk factors, pre-existing heart disease, diabetes, and other relevant complicating conditions.

- **Pap smears:** Young women with HIV infection are at higher risk of cervical cancer than women without HIV infection. A pelvic examination and Pap smear should be repeated at 6 months if normal at baseline, and then repeated annually thereafter— in accordance with the guidelines outlined in Appendix 11, Procedure for Pap Smears, and the information on interpreting Pap smear results that appears above in Section 4, Baseline Medical Evaluation.

### 7. Prophylaxis for Opportunistic Infections (OIs)

#### Indications and Prophylaxis Regimens

Primary prophylaxis for opportunistic infections is indicated for inmates with HIV infection and significant immunosuppression (reduction in CD4+ T cells) to prevent acute illnesses that may require hospitalization. Prophylaxis should be prescribed in accordance with the most recent USPHS recommendations. Specific recommendations for prophylaxis for *Pneumocystis jiroveci*2 pneumonia (PCP), *Toxoplasma gondii*-associated encephalitis, and disseminated infection with *Mycobacterium avium* complex (MAC) are outlined in Appendix 6.

Primary prophylaxis for other opportunistic infections should be initiated in accordance with the following:

**Latent tuberculosis infection:** Persons with HIV infection who are exposed to *M. tuberculosis* have a high risk of developing active TB disease. Treatment of latent TB infection is indicated for inmates with HIV infection who have tuberculin skin test results of 5 millimeters or greater. In addition, inmates who are close contacts of a contagious TB case require treatment for latent TB, regardless of their tuberculin skin test measurement.

---

2 *Pneumocystis jiroveci* (pronounced “yee row vet zee”) is the correct name for what was previously *Pneumocystis carinii*. PCP remains an appropriate abbreviation for pneumocystis pneumonia.
The preferred treatment regimen for latent TB is as follows:

- Isoniazid (900 mg) twice weekly by mouth (separated by at least 2 days), administered under direct observation for 9 months (a total of 78 doses);
- Pyridoxine (usually 50 mg per dose of isoniazid); and
- Baseline liver transaminases tests with monthly assessments for clinical signs and symptoms of hepatotoxicity. Regular monitoring is only required if inmate is at high risk for hepatotoxicity (see the BOP Clinical Practice Guidelines for Management of Tuberculosis at www.bop.gov/resources/health_care_mngmt.jsp#cpg).

Cytomegalovirus (CMV): Primary prophylaxis for CMV infection with oral gancyclovir is not routinely indicated, despite severe immunosuppression (CD4+ T cell counts <50 cells/mm\(^3\)) and positive CMV IgG titers. Although gancyclovir has efficacy as a prophylactic agent, gancyclovir treatment does not increase survival, may promote CMV resistance, and requires a significant pill burden for the patient.

Fungal infections: Primary prophylaxis for fungal infections is not routinely indicated for patients with AIDS. Although primary prophylaxis with fluconazole for oral candidiasis is effective, long-term fluconazole use may promote candidal resistance, is not cost effective, and is less clinically important, since oral candidiasis is usually readily treatable with short-term fluconazole therapy. Primary itraconazole prophylaxis for histoplasmosis (CD4+ T cell count <100 cells/mm\(^3\)) may be considered for inmates with unique indications.

Discontinuation of OI Prophylaxis

Discontinuation of primary and secondary prophylaxis of OIs should be considered on an individual basis, using the following USPHS guidelines:

*Pneumocystis jiroveci* (PCP): Primary and secondary prophylaxis for PCP can be discontinued for inmates whose CD4+ T cell count increases to >200 cells/mm\(^3\) for at least 3 months in response to antiretroviral therapy (ART). Primary or secondary prophylaxis should be reintroduced if the CD4+ T cell count decreases to <200 cells/mm\(^3\) or if PCP reoccurs at a higher CD4+ T cell count.

*Toxoplasma gondii*: Primary prophylaxis for toxoplasmosis encephalitis can be discontinued for inmates whose CD4+ T cell count increases to >200 cells/mm\(^3\) for at least 3 months in response to ART. Secondary prophylaxis (chronic maintenance) for toxoplasmosis can be discontinued on an individual basis for asymptomatic inmates whose CD4+ T cell count has increased to >200 cells/mm\(^3\) for at least 6 months in response to ART. Primary or secondary prophylaxis should be reinitiated if the CD4+ T cell count decreases to <200 cells/mm\(^3\).

*Mycobacterium avium complex* (MAC): Primary prophylaxis for disseminated MAC disease can be discontinued for inmates whose CD4+ T cell count increases to >100 cells/mm\(^3\) for at least 3 months. Secondary prophylaxis (chronic maintenance) for disseminated MAC disease can be discontinued on a case-by-case basis for asymptomatic inmates who have successfully completed a 12-month course of MAC treatment, and have a sustained increase in their CD4+ T cell count, i.e., >100 cells/mm\(^3\) for at least 6 months on an ART regimen.
Cytomegalovirus (CMV): Secondary prophylaxis (chronic maintenance) for CMV can be discontinued for inmates with a history of CMV retinitis on an individual basis, in consultation with the treating ophthalmologist, if the CD4+ T cell count increases to >100 cells/mm$^3$ for 3-6 months in response to ART. Factors to consider before discontinuing secondary prophylaxis include inmate adherence to ART, the location and extent of retinal disease, and the vision in the contralateral eye. Close follow-up with an ophthalmologist is indicated. Prophylaxis should be reinitiated if the CD4+ T cell count decreases to <100 cells/mm$^3$.

Fungal infections: Guidelines for discontinuation of prophylaxis for fungal infections are outlined below:

- **Cryptococcal meningitis:** Secondary fluconazole prophylaxis (chronic maintenance) for cryptococcal meningitis can be discontinued on an individual basis for asymptomatic inmates whose CD4+ T cell count increases to ≥200 cells/mm$^3$ for at least 6 months in response to ART. Reinitiate fluconazole if the CD4+ T cell count declines to <200 cells/mm$^3$.

- **Histoplasmosis:** Inmates with prior histoplasmosis ordinarily require prolonged secondary prophylaxis with oral itraconazole (200 mg twice daily). Secondary prophylaxis/chronic maintenance therapy can be discontinued if the following criteria are fulfilled:
  1. Itraconazole for ≥1 yr,
  2. Negative blood cultures,
  3. CD4+ count >150 cells/mm$^3$ for >6 months in response to ART,
  4. Serum histoplasma antigen <2 units.

- **Coccidioidomycosis:** Inmates with prior coccidioidomycosis ordinarily require lifelong secondary prophylaxis with either oral fluconazole (400 mg daily) or oral itraconazole (200mg twice daily).

**Treatment of Opportunistic Infections**

Inmates diagnosed with OIs related to HIV infection should be treated and maintained on secondary prophylaxis, based upon the current DHHS guidelines (available at [http://www.aidsinfo.nih.gov/guidelines/](http://www.aidsinfo.nih.gov/guidelines/)).
8. Treatment: Antiretroviral Therapy (ART)

8a. Treatment Goals

Eradication of HIV infection cannot be achieved with available ART regimens because of the pool of latently infected CD4 T-cells that persist despite prolonged suppression of plasma viremia. Maximal and durable suppression of plasma viremia delays or prevents the selection of drug-resistance mutations, preserves CD4 T-cell numbers, and confers substantial clinical benefits.

Therefore the primary goals for initiating ART are to:

- Reduce HIV-associated morbidity and prolong the duration and quality of survival.
- Restore and preserve immunologic function.
- Maximally and durably suppress plasma HIV viral load,
- Prevent HIV transmission.

HIV suppression with ART may also decrease the inflammation and immune activation thought to contribute to higher rates of cardiovascular disease and other end-organ damage that are reported in HIV-infected cohorts.

Achieving viral suppression requires the use of ARV regimens with at least two, and preferably three, active drugs from two or more drug classes. Baseline resistance testing and patient characteristics should guide the specific regimen design. When viral suppression is not achieved or is lost, rapidly changing to a new regimen with at least two, and preferably three, active drugs is required.

Viral load reduction to below detection limits in ART-naïve patients usually occurs within the first 12–24 weeks of therapy. Virologic success can be predicted, based on: excellent adherence to highly potent ARV regimens, low baseline viremia, higher baseline CD4 counts, and rapid reduction of viremia in response to treatment.

8b. Initiating Antiretroviral Therapy in Treatment-Naïve Patients

Use of CD4 Counts for Initial Assessment

The CD4 count is one of the most important factors in the decision to initiate ART and/or prophylaxis for opportunistic infections, and it is the strongest predictor of subsequent disease progression and survival. A significant change between two tests is approximately a 30% change in absolute count, or an increase or decrease in CD4 percentage by 3 percentage points.

Viral Load Testing

Viral load testing serves as a surrogate marker for treatment response and can be useful in predicting clinical progression. The minimal change in viral load considered to be statistically significant is a 3-fold change. Optimal viral suppression is generally defined as a viral load consistently below the level of detection. Isolated “blips” (viral loads
transiently detectable at <400 copies/ml) and low-level positive viral load results (<200 copies/ml) are not thought to predict virologic failure. **Virologic failure** is defined as confirmed viral load >200 copies/ml, which may also be useful in clinical practice.

### HIV Drug-Resistance Testing

HIV drug-resistance testing is recommended for persons with HIV infection when they enter into care, and genotypic testing is the preferred resistance testing to guide therapy in ARV-naïve patients.

➤ **See Appendix 12, Recommendations for Using Drug-Resistance Assays.**

### Recommendations for Initiating Therapy

➤ The rating scheme for the DHHS recommendations is described in **Appendix 7**.

Decisions about initiating antiretroviral therapy should be made as recommended below. These BOP guidelines are based on the current DHHS Guidelines presented in **Appendix 8**.

- Antiretroviral therapy (ART) is recommended for all HIV-infected individuals to reduce the risk of disease progression. The strength and evidence for this recommendation vary by pretreatment CD4 cell count:
  - CD4 count <350 cells/mm³ (AI)
  - CD4 count 350–500 cells/mm³ (AII)
  - CD4 count >500 cells/mm³ (BIII)

- ART also is recommended for HIV-infected individuals for the prevention of transmission of HIV:
  - perinatal transmission (AI)
  - heterosexual transmission (AI)
  - other transmission risk groups (AIII)

- Patients with CD4 counts >500 cells/mm³ should be evaluated on a case-by-case basis when considering ART. Those starting ART should be willing and able to commit to treatment and understand the benefits and risks of therapy and the importance of adherence (AIII). Patients may choose to postpone therapy, and providers, on a case-by-case basis, may elect to defer therapy on the basis of clinical and/or psychosocial factors.

**The following conditions favor a more rapid initiation of ART:**

*Note: List continues on next page.*

- Pregnancy
- HIV-associated nephropathy
- Low CD4 counts
- AIDS defining conditions
- Opportunistic diseases
- HBV coinfection (see **Considerations for Antiretroviral Use in Patients with Coinfections**)
- Rapidly declining CD4 counts, e.g., >100 cells/mm³ decrease per year
Higher viral loads, e.g., >100,000
- Age >60
- High-risk behavior

**Conditions where temporary deferral of therapy might be considered:**
- Deferring treatment for patients who have higher CD4 counts and who are at risk of poor adherence may be prudent while the barriers to adherence are being addressed.
- Consideration should be given to situations, within the BOP system, in which the patient may be better served by delaying treatment (e.g., short length of stay, hold-over/transfer status).

**Adherence Considerations**

Strict adherence to antiretroviral therapy is necessary for drug effectiveness and prevention of drug resistance. *Patient adherence should be assessed individually:*

- Known predictors of poor adherence to HIV treatment regimens include low levels of literacy, age-related challenges, psychosocial issues, substance abuse, difficulty taking medication, complex regimens, adverse drug effects, and treatment fatigue.
- It is critical that inmate education by clinicians, pharmacists, and the nursing staff take place before initiating complicated antiretroviral drug treatment regimens.
- Counseling should include a discussion of the risks and benefits of ART, potential drug side effects, methods for managing side effects, instructions for taking scheduled medications by dose and time, and the need to report missed doses. *Mental health conditions should be evaluated, treated, and stabilized prior to initiating antiretroviral therapy.*

**Antiretroviral medications should initially be administered by direct observation on a dose-by-dose or daily basis:**

- Directly observed medication delivery should be maintained or gradually changed to inmate self-administration at the discretion of the treating physician, based on patient adherence and the virologic response to therapy.
- Soon-to-be-released inmates on directly observed antiretroviral medications should be gradually transitioned to a self-administration regimen prior to release.

**Table 6. Strategies to Improve Adherence to Antiretroviral Therapy**

- Use a multidisciplinary team approach (i.e., medical, nursing, pharmacy, dental, etc.). Provide an accessible, trusting health care team. Provide education on medication dosing.
- Establish a trusting relationship with the patient.
- Establish readiness to start ART.
- Identify potential barriers to adherence prior to starting ART.
- Provide resources for the patient.
- Involve the patient in antiretroviral (ARV) regimen selection.
- Assess adherence at every clinic visit.
- Identify the type of non-adherence.
- Identify reasons for non-adherence.
- Assess and simplify regimen, if possible.

8c. What to Start: Initial Combination Regimens for the Antiretroviral-Naïve Patient

The selection of an initial antiretroviral treatment regimen should ordinarily be consistent with the DHHS preferred regimens. See Appendix 9 for a description of the DHHS guidelines and a discussion of the advantages and disadvantages of different initial regimens.

Preferred Regimens

The following regimens are preferred because they have optimal and durable efficacy, a favorable tolerability and toxicity profile, and ease of use.

(1) **Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen:**
   - Efavirenz 600mg/emtricitabine 200mg/tenofovir 300mg once daily.
   *Note: Efavirenz should not be used during the first trimester of pregnancy or in women trying to conceive or not using effective and consistent contraception.*

(2) **Protease inhibitor (PI)-based regimens:**
   - Atazanavir 300mg/ritonavir 100mg + emtricitabine 200mg/tenofovir 300mg once daily.
   *Note: Atazanavir/ritonavir should not be used in patients who require >20mg of omeprazole equivalent per day.*
   - Davunavir 800mg/ritonavir 100mg + emtricitabine 200mg/tenofovir 300mg once daily.

(3) **Integrase strand transfer inhibitor (INSTI)-based regimen:**
   - Raltegravir 400mg twice daily + emtricitabine 200mg/tenofovir 300mg once daily.

(4) **Preferred Regimens for Pregnant Women**
Alternative Regimens

The following regimens are effective and tolerable, but have potential disadvantages compared to the preferred regimens

**Note:** Alternative regimens that include abacavir require screening for HLA-B 5701 before starting patients on abacavir. HLA-B 5701-positive patients should not be prescribed abacavir.

(1) **NNRTI-BASED REGIMENS:**
- Efavirenz + abacavir/lamivudine
- Rilpivirine/tenofovir/emtricitabine

*Note: RPV is not recommended in patients with pretreatment HIV RNA >100,000 copies/mL.*

(2) **PI-BASED REGIMENS:**
- Atazanavir/ritonavir + abacavir/lamivudine
- Darunavir/ritonavir + abacavir/lamivudine
- Fosamprenavir/ritonavir + either abacavir/lamivudine) or emtricitabine/tenofovir
- Lopinavir/Ritonavir + either abacavir/lamivudine) or emtricitabine/tenofovir

(3) **INSTI-BASED REGIMENS:**
- Elvitegravir + cobicistat + tenofovir + emtricitabine

**Notes Regarding Initial Regimens:**

- The following combinations listed above are available as fixed-dose combination formulations: ABC/3TC, EFV/TDF/FTC, EVG/COBI/TDF/FTC, LPV/r, RPV/TDF/FTC, TDF/FTC, and ZDV/3TC.

- **Appendix 10** lists antiretroviral medications that should *never be prescribed*, and those that should *not be prescribed as initial therapy*.

- FDA-approved antiretroviral medications and their dosing recommendations are enumerated in the DHHS guidelines. Clinicians managing inmates with HIV infection should regularly review the DHHS guidelines to keep abreast of new FDA-approved antiretroviral medications, changes in antiretroviral dosages, drug side effects and adverse reactions, monitoring parameters, and complex drug interactions. The DHHS guidelines are available at: [http://www.aidsinfo.nih.gov/guidelines/](http://www.aidsinfo.nih.gov/guidelines/)

- See **Table 7** below for a comparison of NNRTI-based and PI-based regimens.
Comparison of Preferred Regimens

Table 7 compares the advantages and disadvantages of NNRTI-based and PI-based regimens:

<table>
<thead>
<tr>
<th>Table 7. Comparison of Preferred Regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Advantages</strong></td>
</tr>
<tr>
<td><strong>NNRTI-Based Regimen (Efavirenz + TDF/FTC)</strong></td>
</tr>
<tr>
<td>• NNRTI-based regimens have demonstrated virologic potency and durability.</td>
</tr>
<tr>
<td>• A single tablet co-formulated with TDF, FTC, and EFV provides single-tablet, once-daily dosing and is currently the preferred NNRTI-based regimen.</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>PI-Based Regimen</strong></td>
</tr>
<tr>
<td>• PI-based regimens have higher genetic barrier to resistance than NNRTIs and RAL.</td>
</tr>
<tr>
<td>• PI resistance at the time of treatment failure is uncommon with RTV-boosted PIs.</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Integrate Strand Transfer Inhibitor – INSTI-Based Regimen (Raltegravir)</strong></td>
</tr>
<tr>
<td>• Fewer drug-related adverse events and lipid changes than with EFV.</td>
</tr>
<tr>
<td>• Virologic response non-inferior to EFV; superior at 4–5 years.</td>
</tr>
<tr>
<td>• Fewer drug-drug interactions than with PI-, NNRTI-, or MVC-based regimens.</td>
</tr>
<tr>
<td>• No food effect.</td>
</tr>
</tbody>
</table>
Immune Reconstitution

Effective antiretroviral therapy may result in immune reconstitution with paradoxical inflammatory reactions to certain pathogens. These acute reactions can include inflammatory masses or adenitis related to *M. avium* infection, active tuberculosis, viritis associated with CMV infection, cryptococcal meningitis, active hepatitis B and C, and herpes zoster. Illnesses secondary to immune reconstitution ordinarily do not require discontinuation of antiretroviral therapy.

8d. Management of the Treatment-Experienced Patient

Virologic and Immunologic Definitions

- **Virologic suppression:** A confirmed HIV RNA level below the limit of assay detection (e.g., <20 to 75 copies/ml, depending on the assay used).

- **Virologic failure:** The inability to achieve or maintain suppression of viral replication (to an HIV RNA level <200 copies/ml).

- **Incomplete virologic response:** Two consecutive plasma HIV RNA levels >200 copies/ml after 24 weeks on an ARV regimen. Baseline HIV RNA may affect the time course of response, and some regimens will take longer than others to suppress HIV RNA levels.

- **Virologic rebound:** Confirmed detectable HIV RNA (to >200 copies/ml) after virologic suppression.

- **Persistent low-level viremia:** Confirmed detectable HIV RNA levels that are <1,000 copies/ml.

- **Virologic blip:** After virologic suppression, an isolated detectable HIV RNA level that is followed by a return to virologic suppression.

Assessment of Virologic Failure

It is important to distinguish among the reasons for virologic failure because the approaches to subsequent therapy differ. The following potential causes of virologic failure should be explored in depth.

- **Adherence:** Assess the patient’s adherence to the regimen and address the underlying causes. Simplify the regimen if possible.

- **Medication intolerance:** Assess the patient’s tolerance of the current regimen and consider the following management strategies:
  - Symptomatic treatment (e.g., antiemetics, antidiarrheals).
  - Changing one ARV to another within the same drug class.
  - Changing from one drug class to another.

- **Pharmacokinetic issues:** Assess/review the following underlying causes:
  - Food/fasting requirements for each medication.
  - Gastrointestinal symptoms (vomiting/diarrhea) causing short-term malabsorption.
► Concomitant medications/dietary supplement resulting in drug interaction and make appropriate substitutions.
► Consider therapeutic drug monitoring when pharmacokinetic issues are suspected.

- **Suspected drug resistance:**
  ► Obtain resistance testing while the patient is taking the failing regimen, or within 4 weeks after regimen discontinuation if the plasma HIV RNA level is >500 copies/ml.
  ► Evaluate the degree of drug resistance from the current resistance test, understanding that drug resistance tends to be cumulative for a given individual; thus, all prior treatment history and resistance test results should be taken into account.
  ► Genotypic and phenotypic testing provides information relevant for selecting a new regimen with a better virologic response.

### Changing ART

Consult with a physician who has HIV treatment expertise and/or a BOP HIV Clinical Pharmacist before initiating an alternative regimen. Consider the following guidance:

- The goal of ART is to suppress HIV replication to a level where drug-resistance mutations do not emerge.
- Selection of drug resistance does not appear to occur in patients with persistent HIV RNA levels suppressed to <48 copies/ml.
- Persistent HIV RNA levels >200 copies/ml often are associated with evidence of viral evolution and drug-resistance mutation accumulation. Persistent plasma HIV RNA levels in the 200–1,000 copies/ml range should therefore be considered as virologic failure.
- Viremia “blips” (e.g., viral suppression followed by a detectable HIV RNA level, and then subsequent return to undetectable levels) usually are not associated with subsequent virologic failure.

### Management of Virologic Failure

Clinical scenarios can be reviewed in the DHHS guidelines, which include the following guidance:

- Once virologic failure is confirmed, generally the regimen should be changed as soon as possible to avoid progressive accumulation of resistance mutations.
- New ARV regimen should contain at least two, and preferably three, fully active drugs on the basis of drug treatment history, resistance testing, or new mechanistic class. *Adding a single, fully active ARV in a new regimen is not generally recommended because of the risk of rapid development of resistance.*
- Because of the potential for drug-class cross resistance that reduces drug activity, using a “new” drug that a patient has not yet taken may not mean that the drug is fully active.
• Factors associated with better virologic responses to subsequent regimens:
  ► Lower HIV RNA level and/or higher CD4 cell count at the time of therapy change.
  ► Using a new (i.e., not yet taken) class of ARV drugs.
  ► Using ritonavir-boosted PIs in PI-experienced patients.
• Higher genotypic and/or phenotypic susceptibility scores (quantitative measures of drug activity) are associated with better virologic responses.
• Patients who receive more active drugs have a better and more prolonged virologic response than those with fewer active drugs in the regimen.
• Discontinuing or briefly interrupting therapy in a patient with viremia may lead to a rapid increase in HIV RNA and a decrease in CD4 T-cell count, which increases the risk of clinical progression. Therefore, this strategy is not recommended.

8e. Regimen Simplification

Regimen simplification can be defined broadly as a change in established effective therapy to reduce pill burden and dosing frequency, to enhance tolerability, or to decrease specific food and fluid requirements. Systematic reviews in the non-HIV literature have shown that adherence is inversely related to the number of daily doses. Review the DHHS Guidelines for suggested candidates for regimen simplification and the types of treatment simplification. ART simplification should normally be accomplished in consultation with a physician who has HIV treatment expertise and/or a BOP HIV Clinical Pharmacist.

8f. Discontinuation or Interruption of ART

Discontinuing ART may result in viral rebound, immune decompensation, and clinical progression although an unplanned interruption of ART may become necessary because of severe drug toxicity, intervening illness, surgery that precludes oral therapy, or unavailable antiviral medication. Review the DHHS guidelines for guidance in discontinuing ART. Discontinuing ART should normally be accomplished in consultation with a physician who has HIV treatment expertise and/or a BOP HIV Clinical Pharmacist.

Guidance regarding interruptions of ART:

• Unanticipated need for short-term interruption: When a patient experiences a severe or life-threatening toxicity or unexpected inability to take oral medications—all components of the drug regimen should be stopped simultaneously, regardless of drug half-life.
• Planned short-term interruption (1–2 days): Stopping ARV drugs for a short time (i.e., 1 to 2 days) due to medical/surgical procedures can usually be done by holding all drugs in the regimen.
• Planned short-term interruption (>2–3 days):
  ► When all regimen components have similar half-lives and do not require food for proper absorption—all drugs may be given with a sip of water, if allowed; otherwise, all drugs should be stopped simultaneously. All discontinued regimen components should be restarted simultaneously.
► When all regimen components have similar half-lives and require food for adequate absorption, and the patient cannot take anything by mouth for a sustained period of time—temporary discontinuation of all drug components is indicated. The regimen should be restarted as soon as the patient can resume oral intake.

► When the ARV regimen contains drugs with differing half-lives—stopping all drugs simultaneously may result in functional monotherapy with the drug with the longest half-life (typically a non-nucleoside reverse transcriptase inhibitor—NNRTI).

Guidance regarding discontinuing therapy with NNRTIs:

NNRTIs (efavirenz and nevirapine) have a long half-life, remaining in the blood after other antiretroviral drugs have cleared. For this reason, patients taking regimens containing an NNRTI are at risk of developing resistance to the NNRTI following cessation of the regimen.

- **The optimal strategy for safely stopping an NNRTI-containing regimen is uncertain**, but potential options include: (1) discontinue the NNRTI and substitute a PI for 4 weeks, and then stop all drugs together; or (2) discontinue the NNRTI and continue other drugs for 1 additional week

- ** Interruption of therapy after pregnancy:** ARV drugs for prevention of perinatal transmission of HIV are recommended for all pregnant women, regardless of whether they have indications for ART for their own health. Following delivery, considerations regarding continuation of the ARV regimen for maternal therapeutic indications are the same as for other nonpregnant individuals.

8g. Considerations for Antiretroviral Use in Patients with Coinfections

**Hepatitis B/HIV Coinfection**

Review the DHHS Guidelines for additional information, which includes the following guidance:

- Prior to initiation of ART, all patients who test positive for hepatitis B surface antigen (HBsAg) should be tested for hepatitis B virus (HBV) DNA using a quantitative assay to determine the level of HBV replication.

- Because emtricitabine (FTC), lamivudine (3TC), and tenofovir (TDF) have activity against both HIV and HBV, if HBV or HIV treatment is needed, ART should be initiated with the combination of TDF + FTC or TDF + 3TC as the nucleoside reverse transcriptase inhibitor (NRTI) backbone of a fully suppressive antiretroviral (ARV) regimen.

- If HBV treatment is needed and TDF cannot safely be used, the alternative recommended HBV therapy is entecavir in addition to a fully suppressive ARV regimen. Other HBV treatment regimens include peginterferon alfa monotherapy or adefovir in combination with 3TC or FTC or telbivudine in addition to a fully suppressive ARV regimen.

- Entecavir has activity against HIV; its use for HBV treatment without ART in patients with dual infection may result in the selection of the M184V mutation that confers HIV resistance to 3TC and FTC. Therefore, entecavir must be used in addition to a fully suppressive ARV regimen when used in HIV/HBV-coinfected patients.
Discontinuation of agents with anti-HBV activity may cause serious hepatocellular damage resulting from reactivation of HBV; patients should be advised against self-discontinuation and carefully monitored during interruptions in HBV treatment.

If ART needs to be modified due to HIV virologic failure, and the patient has adequate HBV suppression, the ARV drugs active against HBV should be continued for HBV treatment in combination with other suitable ARV agents to achieve HIV suppression.

Hepatitis C/HIV Coinfection

Review the DHHS Guidelines for additional information, which includes the following guidance.

- All HIV-infected patients should be screened for hepatitis C virus (HCV) infection, preferably before starting ART.

- ART may slow the progression of liver disease by preserving or restoring immune function and reducing HIV-related immune activation and inflammation. For most HIV/HCV-coinfected patients, including those with cirrhosis, the benefits of ART outweigh concerns regarding drug-induced liver injury (DILI). Therefore, ART should be considered for HIV/HCV-coinfected patients, regardless of CD4 count.

- Initial ART combination regimens for most HIV/HCV-coinfected patients are the same as those for individuals without HCV infection. However, when treatment for both HIV and HCV is indicated, consideration of potential drug-drug interactions and overlapping toxicities should guide ART regimen selection or modification.

- Combined treatment of HIV and HCV can be complicated by large pill burden, drug interactions, and overlapping toxicities. Although ART should be initiated for most HIV/HCV-coinfected patients regardless of CD4 cell count, some clinicians may choose to defer ART for ART-naive patients with CD4 counts >500 cells/mm³ until completion of HCV treatment.

- In patients with lower CD4 counts (e.g., <200 cells/mm³), it may be preferable to initiate ART and delay HCV therapy until CD4 counts increase as a result of ART.

- Concurrent treatment of both HIV and HCV is feasible with the following notable considerations:
  - Didanosine (ddI) should not be given with ribavirin because of the potential for drug-drug interactions.
  - Zidovudine (ZDV) combined with ribavirin should be avoided when possible because of the higher rates of anemia.
  - Abacavir (ABC) has been associated with decreased response to peginterferon plus ribavirin in some, but not all, retrospective studies; current evidence is insufficient to recommend avoiding this combination.
  - Growth factors (e.g., filgrastim and erythropoietin) may be required to manage interferon-associated neutropenia and ribavirin-associated anemia.
  - Boceprevir can be co-administered with RAL.
Co-administration of boceprevir with ATV/r, DRV/r, LPV/r, or efavirenz (EFV) is not recommended because of bidirectional drug interactions.

Telaprevir can be co-administered with ATV/r and RAL at the standard recommended dose of telaprevir (750 mg every 7–9 hours) and with EFV at an increased dose of telaprevir (1125 mg every 7–9 hours).

Co-administration of telaprevir with DRV/r, fosamprenavir/ritonavir (FPV/r), or LPV/r is not recommended because of bidirectional drug interactions.

Note: Preliminary recommendations for the use of boceprevir or telaprevir in HIV patients infected with HCV are available in the DHHS Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Recommendations may be modified as new information becomes available and the latest guidelines should be referenced.

Tuberculosis/HIV Co-Infection

Review the DHHS Guidelines for additional information, which includes the following guidance:

- The treatment of active tuberculosis (TB) disease in patients with HIV infection should follow the same principles for persons without HIV infection.

- All HIV-infected patients with the diagnosis of active TB should be started on TB treatment immediately and should also continue ART. If the patient is not yet on ART, it should be initiated under the following guidelines:
  - In patients with CD4 counts < 50 cells/mm³, ART should be initiated within 2 weeks of starting TB treatment.
  - In patients with CD4 counts ≥50 cells/mm³ who present with clinical disease of major severity as indicated by clinical evaluation (including low Karnofsky score, low body mass index, low hemoglobin, low albumin, organ system dysfunction, or extent of disease), ART should be initiated within 2 to 4 weeks of starting TB treatment.
  - In patients with CD4 counts ≥50 cells/mm³ who do not have severe clinical disease, ART can be delayed beyond 2 to 4 weeks of starting TB therapy but should be started within 8 to 12 weeks of TB therapy initiation.

- Despite pharmacokinetic drug interactions, a rifamycin (rifampin or rifabutin) should be included in TB regimens for patients receiving ART, with dosage adjustment if necessary.

- Immune reconstitution inflammatory syndrome (IRIS) may occur after initiation of ART. Both ART and TB treatment should be continued while managing IRIS.

- ARV regimens should be assessed with particular attention to potential pharmacokinetic interactions with rifamycins. The patient’s regimen may need to be modified to permit use of the optimal TB treatment regimen.
8h. Dental Management

The provision of dental care to patients with HIV disease should be based on the overall health status of the patient, not solely on HIV status (CD4 counts). A thorough review of a patient’s health history should be conducted. Knowing the progression of HIV is important as there is a broad spectrum of associated diseases and oral manifestations.

It is important to note that patients may not know their HIV status. Dental providers may be the first health care provider to encounter symptomatic disease. Keen oral health examination, including soft tissue palpation of the head and neck, is important in this disease. Along with managing the oral effects secondary to this disease, classification conditions can first be identified in the oral cavity (see Appendix 5, HIV Classification System) or during the head and neck exam. Prompt identification and referral to medical providers facilitates the team management of these patients. Medical staff should refer HIV inmates to the dental clinic for co-management when oral conditions have been identified at the time of their medical encounters.

The presence of rampant caries, aggressive periodontal disease, and soft tissue lesions/conditions require attentive treatment management or referral. Frequent periodontal recalls (every 3 to 6 months) may be warranted for some patients. Emphasis on self-care and prevention is critical in this patient population. Any prescriptions must be based on careful consideration of the possibility of adverse drug effects.

There are some general pretreatment considerations for HIV infected patients. Special attention to medications is particularly important when prescribing antibiotics, as patients may already be on aggressive regimens. Some medications may cause xerostomia, resulting in extensive caries. Patients on long-term antiretroviral medications should be evaluated for neutropenia. Patients with severe neutropenia (absolute neutrophil counts < 500) should be provided prophylactic antimicrobials for all dental procedures. Moreover, it should be noted that the presence of oral lesions in patients who appear to have responded well to antiviral therapy and have undetectable HIV viral load may suggest treatment failure. Referral to the patient’s primary care provider is indicated.

Once the possibility of significant immunosuppression, neutropenia, or thrombocytopenia has been ruled out, HIV-infected patients usually do not require special consideration when providing dental treatment. It is essential that dental staff work collaboratively with medical providers in fostering a team approach to patient care.

<table>
<thead>
<tr>
<th>CD4 Cells/mm³: Disease Progression</th>
<th>Management Considerations</th>
</tr>
</thead>
</table>
| **400–600:** Initial immune suppression | • Review health history.  
• Check recent labs (CBC with differential current within 6 months).  
• Emphasize preventive dentistry.  
• Use chlorhexidine rinses before dental procedures to reduce microbial load.  
• Consult with primary care provider if opportunistic infections are present.  
• Treat oral candidiasis and ulcerative lesions.  
• Consider biopsy for non-responsive oral lesions. |
| **200–400:** Emergence of opportunistic infections |  |
| **≤ 200:** Severe immune suppression | • All of the above.  
• Primary care provider should be contacted for pretreatment medical consultation.  
• Review health history and labs:  
  ▶ *Determine if patient is neutropenic (absolute neutrophil counts <500):* Prophylactic antimicrobials for severe neutropenic patients.  
  ▶ *Determine if patient has idiopathic Thrombocytopenia Purpura (ITP):* Obtain pre-surgical platelet counts for patient procedures, which include scaling and curettage.  
• Avoid aspirin and NSAIDs as analgesics.  
• Patients with rampant caries and or poor salivary flow are not good candidates for extensive restorations. Consider glass ionomers.  
• Regular periodontal appointments should be provided for inmates with HIV-associated periodontal disease. |
8i. Pregnancy

8j. Wasting Syndrome
The CDC defines the HIV wasting syndrome as progressive, involuntary weight loss (10% reduction in baseline body weight) plus chronic diarrhea, chronic weakness, or documented fever in the absence of an explanatory concurrent illness or condition. Smaller reductions in weight (5–10%) without associated symptoms, however, may be clinically significant in persons with HIV infection, particularly when complicated by AIDS. Other potential causes of weight loss such as active TB, malignancies, drug side effects, depression, and opportunistic infections associated with AIDS should be actively identified and treated. Effective antiretroviral therapy should be initiated or improved in order to maximize HIV RNA suppression. Oral nutritional supplements ordinarily do not provide any additional benefit to a healthy diet.

8k. Adverse Drug Reactions
Antiretroviral dosing, side effects, monitoring parameters, and potential drug interactions should be carefully reviewed. See the DHHS guidelines, prior to prescribing or changing antiretroviral therapy, and consider the following:

• Adverse effects have been reported with all ARV drugs and are among the most common reasons for switching or discontinuing therapy, as well as for medication nonadherence.

• Rates of treatment-limiting adverse events in ART-naïve patients enrolled in randomized trials appear to be declining with newer ARV regimens, and are generally now less than 10%.

• Factors may predispose individuals to adverse effects of ARV medications:
  ► Women seem to have a higher propensity of developing Stevens-Johnson syndrome, rashes, and hepatotoxicity from nevirapine, as well as higher rates of lactic acidosis from nucleoside reverse transcriptase inhibitors (NRTIs).
  ► Reactions can result from concomitant use of medications with overlapping and additive toxicities.
  ► Comorbid conditions that may increase the risk of or exacerbate adverse effects (e.g., alcoholism or coinfection with viral hepatitis, which may increase risk of hepatotoxicity).
  ► Drug-drug interactions that may lead to an increase in dose-related toxicities.
  ► Genetic factors predisposing patients to abacavir (ABC) hypersensitivity reaction.
9. Transition to the Community

Continuity of prescribed treatments, particularly antiretroviral medications, is medically critical for inmates who are released directly to the community or to community placement facilities such as halfway houses. Preparation for transitional medical needs should be initiated well in advance of anticipated release, in accordance with the following guidelines:

• Release planning should be coordinated with the inmate’s case manager and community corrections staff, in accordance with BOP policy.

• The inmate’s primary provider or other knowledgeable health care provider should meet with the inmate to finalize the treatment plan and ensure that the inmate understands the importance of adherence to prescribed treatments and specific follow-up instructions.

• Specific efforts should be made by BOP staff to coordinate access to federally funded drug assistance programs such as ADAP (AIDS Drug Assistance Program), as well as other recommended treatments such as mental health care and substance abuse programs. Consultation with BOP social workers should be pursued on a case-by-case basis to assist with release planning efforts.

• A consent for release of medical information should be obtained from the inmate, in accordance with BOP policy, so that the inmate’s treatment plan can be discussed with the community health care provider.

• An adequate supply of medications should be provided to the inmate prior to release or during community placement, in accordance with BOP policy.

10. Infection Control

Transmission

HIV is spread primarily through percutaneous blood exposures such as injection drug use, unprotected vaginal and anal intercourse, and transfusion of contaminated blood products (received prior to 1985). HIV is also transmitted from mother to child perinatally during pregnancy and through breastfeeding. HIV is not spread by sneezing, hugging, coughing, sharing eating utensils and drinking glasses, or casual contact; nor is it spread in food or water.

All inmates should be counseled during orientation to the institution, and when appropriate during clinical evaluations, of the importance of preventing blood exposures to others during activities of daily living.

These counseling messages should be reinforced for all inmates diagnosed with HIV infection:

• Do not have sex while in prison; do not have unprotected sex upon release to the community.

• Do not shoot drugs.

• Do not share tattooing or body piercing equipment.

• Do not share personal items that might have your blood on them such as toothbrushes, dental appliances, nail clippers or other nail-grooming equipment, or razors.

• Cover your cuts and skin sores to keep your blood from contacting other persons, and report to your health care provider should you have an open, draining wound.
Additionally, inmates with HIV infection should be given the following guidance:

- Do not donate blood, body organs or other tissue, or semen.
- Always wash hands before eating, after touching contaminated clothing/bedding, after attending to personal hygiene, after gardening or other outdoor activities, after touching animals, or after touching any other contaminated items.
- Wash fresh fruits and vegetables thoroughly before eating.
- Avoid eating undercooked or raw meats.
- Stop smoking, and do not begin smoking again upon release.
- Avoid touching stray animals.

Protecting Correctional Workers

Staff should use the following infection control guidelines when managing inmates:

- Use *correctional standard precautions* (see Definitions) when in contact with any inmate’s blood or other potentially infectious materials, whether or not the inmate is known to have HIV infection.

- Use infection control practices in which non-disposable patient-care items are appropriately cleaned, disinfected, or sterilized, based on the use. Take measures to prevent cross-contamination during patient care (e.g., dialysis, vascular access, cauterizing, or dental procedures), in accordance with the Centers for Disease Control Guidelines on Hand Washing and Hospital Environmental Control.

- Use the appropriate airborne, droplet, and/or contact transmission precautions when indicated for inmates with HIV infection who have or may have acute secondary infections that are transmissible by respiratory contact, or by direct hand or skin-to-skin contact.
**Definitions – General**

**CD4+ T cell** is a T-cell lymphocyte that is essential for human cellular immunity. HIV infection results in a decline of CD4+ T cells, immunosuppression, and susceptibility to opportunistic infections.

**Clinician** is a physician, dentist, mid-level provider, or pharmacist with a collaborative practice agreement.

**Directly Observed Therapy (DOT)** for HIV infection is the unit dose administration of antiretroviral medications to an inmate by a clinician, nurse, pharmacist, or specially trained staff person who directly observes ingestion.

**EIA** is Enzyme Immunoassay, a laboratory test for detecting antibodies.

**ART** is highly active, antiretroviral therapy that can achieve sustained, undetectable HIV RNA levels in infected persons.

**HIV RNA Test** is a laboratory assay used to quantitatively measure the presence of HIV viral particles in serum, expressed as copies per milliliter (cps/mL) and referred to as viral load or viral burden. HIV RNA levels are measured for the staging of HIV infection and therapeutic monitoring. Standard and ultrasensitive assays are available.

**Immune Reconstitution** is the regaining of functional CD4+ T cells (host cellular immunity) following treatment of a previously immunocompromised condition such as AIDS. Immune reconstitution in the context of HIV infection results from effective antiretroviral therapy and may paradoxically be associated with inflammatory reactions to certain pathogens such as *M. tuberculosis*, cytomegalovirus, and *M. avium* complex.

**Resistance Testing** for HIV refers to genotypic and phenotypic assays that assess HIV resistance to specific antiretroviral drugs. **Genotypic assays** measure specific mutations to viral enzymes (reverse transcriptase/protease). **Phenotypic assays** measure the ability of HIV to grow in various concentrations of antiretroviral drugs.

**Undetectable HIV** is the measurement of HIV RNA at levels that are below the level of detectability of specific assays, <48 cps/mL.
Definitions – Infection Control Precautions

Infection control precautions include the following categories of precautions relevant to the correctional setting.

**STANDARD PRECAUTIONS** apply to blood and all other body fluids, secretions, and excretions (except sweat), whether or not they contain visible blood; nonintact skin; and mucous membranes. Standard precautions include:

- Adequate hand hygiene measures in accordance with CDC guidelines after touching blood, body fluids, secretions, excretions (including wound drainage), and contaminated items, whether or not gloves are worn.
- Routine use of personal protective equipment such as gloves, masks, eye protection or face shields, and gowns whenever contact with blood, body fluids, secretions, excretions (including wound drainage) is anticipated.
- Ensuring that environmental surfaces in the health care setting are routinely cleaned and disinfected.
- Ensuring that linens are handled and cleaned in a manner that prevents staff exposure to contaminated laundry and that avoids the transfer of microorganisms from person to person, or from place to place.
- Safe disposal of needles and other sharp instruments and devices in appropriate leak-proof and puncture-resistant containers.
- Placing in a private room those patients who may contaminate the environment or cannot be expected to maintain adequate hygiene or a sanitary environment.
- **Full surface disinfection of the dental operatory when invasive procedures are performed, exacerbated by the aerosolization blood and saliva.**

**HOSPITAL STANDARD PRECAUTIONS** are infection control practices used in the hospital setting to reduce the risk of transmission of microorganisms from both recognized and unrecognized sources of infection.

**CORRECTIONAL STANDARD PRECAUTIONS** are *hospital standard precautions* that have been adapted to the correctional setting by taking into account security issues, inmate housing factors, and infection control concerns inherent in jails and prisons.

⇒ See the relevant appendices in the *BOP Clinical Practice Guidelines for the Management of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections*, available at [www.bop.gov/resources/health_care_mngmt.jsp#cpg](http://www.bop.gov/resources/health_care_mngmt.jsp#cpg).

**CONTACT TRANSMISSION PRECAUTIONS** are indicated for inmates with pediculosis, scabies, impetigo, and noncontained skin infections such as abscesses, cellulitis, and decubiti; viral conjunctivitis; certain highly contagious enteric infections such as *Clostridium difficile* or diarrhea combined with infection with hepatitis A virus, Shigella, or *Escherichia coli* O157:H7; and gastrointestinal, respiratory, skin, or wound infections or colonization with certain multi-drug resistant bacteria such as methicillin-resistant *Staphylococcus aureus* (MRSA).
Contact transmission precautions include routine *standard precautions*, as well as the following additional measures:

- The inmate should be placed in a private cell. Inmates with the same infection can be housed together if single-cell status is not feasible.
- Clean, nonsterile gloves should be worn when entering the cell. Gloves should be changed when grossly contaminated with potentially infectious material such as fecal material and wound drainage. Gloves must be removed and hands cleaned immediately (by washing with an antimicrobial agent or by using a waterless antiseptic agent) *before* leaving the inmate’s cell. Once hands have been cleaned, care must be taken not to touch potentially contaminated environmental surfaces or items.
- A clean, nonsterile gown should be worn when entering the inmate’s cell whenever direct contact with the inmate or with environmental surfaces or items in the cell is anticipated. The gown should be removed *before* leaving the inmate’s cell, taking care not to have one’s clothing contact potentially contaminated environmental surfaces.
- The inmate should leave his or her cell for essential purposes only. If the inmate leaves the cell, precautions should be taken to minimize the risk of transmitting microorganisms to other persons and to avoid contamination of environmental surfaces or items.
- Noncritical patient care equipment should be dedicated to a single inmate. Common medical equipment that must be shared between patients must be adequately cleaned and disinfected before use by another inmate.
- No special requirements are indicated for eating utensils. Disposable or reusable utensils may be used. The use of detergent and washing procedures for decontamination are sufficient.

**DROPLET TRANSMISSION PRECAUTIONS** are indicated for inmates with illnesses such as influenza, mumps, rubella, streptococcal pharyngitis or pneumonia, invasive *Haemophilus influenzae* type b disease such as pneumonia and epiglottitis, or invasive *Neisseria meningitidis* disease such as meningitis and pneumonia, as well as MRSA pneumonia.

*Note:* *Inmates with an unknown respiratory illness compatible with tuberculosis should be managed with airborne precautions.*

Illnesses requiring droplet precautions are caused by infectious agents that are transmitted in large-particle droplets (>5 μm in size) when an infectious patient coughs, sneezes, talks, or has certain procedures performed such as suctioning and bronchoscopy. Transmission of infection occurs when droplets containing the microorganism are propelled a short distance in the air and then deposited on the host’s mouth, nasal mucosa, or conjunctivae. Large-particle droplets do not remain suspended in the air. Droplet precautions include routine standard precautions, as well as the following measures:

- The inmate should be placed in a private cell (it does not require negative pressure or a special air handling system). The door of the cell may be opened without concern that the infectious agent will be transmitted to others. Inmates with the same infection may be housed together if single-cell housing status is not feasible.
• A mask, eye protection, or a face shield should be worn to protect mucous membranes of the eyes, nose, and mouth during procedures and patient care activities that are likely to generate splashes or sprays. Masks should be worn when entering the cell or when within three feet of the inmate. An N95 respirator is not required.

• Isolated inmates must wear a surgical mask if they must leave their cell. Inmate movement outside the cell should be limited to essential purposes.

**Airborne Transmission Precautions** are protective measures used to prevent the spread of infections such as tuberculosis, varicella (chicken pox), and rubella (measles) that are transmitted by inhalation of microorganisms, 5 μm or smaller in size. These tiny germs can remain suspended in airborne nuclei in poorly circulated air and can be potentially transmitted over long distances from the source patient.

Infection control airborne precautions include the isolation of contagious inmates in a cell with monitored, negative air pressure in accordance with CDC guidelines and BOP policy. Inmates infected with the same microorganism can be cohorted together in the same cell. If a negative pressure cell is not available, the optimal management of the inmate should be determined on a case-by-case basis in consultation with a knowledgeable infection control practitioner.

Staff entering the cell of an inmate who has pulmonary tuberculosis should wear appropriate respiratory protection (i.e., HEPA or N-95 respirators). Susceptible staff should not enter the cell of an inmate who has varicella or measles unless it is absolutely essential, and then only with respiratory protection. Staff who are immune to varicella or measles do not require respiratory protection when entering the cell of an isolated inmate who has varicella or measles. Contagious inmates infected with pathogens transmitted by airborne microorganisms should wear a surgical mask whenever medical or security measures require them to leave the negative-pressure isolation cell.

**Correctional Transmission-Based Precautions** are contact, droplet, and airborne precautions that have been adapted to the correctional setting, taking into account relevant security concerns, inmate housing factors, and infection control issues inherent in jails and prisons. See the relevant appendices in the *BOP Clinical Practice Guidelines for the Management of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections*, available at [www.bop.gov/resources/health_care_mngmt.jsp#cpg](http://www.bop.gov/resources/health_care_mngmt.jsp#cpg).
<table>
<thead>
<tr>
<th>Topic</th>
<th>Title</th>
<th>Link</th>
<th>Agency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resistance Testing</td>
<td>Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection</td>
<td><a href="https://www.iiasusa.org/content/antiretroviral-drug-resistance-testing-adult-hiv-1-infection">https://www.iiasusa.org/content/antiretroviral-drug-resistance-testing-adult-hiv-1-infection</a></td>
<td>IAS-USA</td>
</tr>
</tbody>
</table>

ACIP = Advisory Committee on Immunization Practices; CDC = Centers for Disease Control and Prevention; DHHS = Department of Health and Human Services; IDSA = Infectious Disease Society of America; IAS-USA = International AIDS Society-USA; NIH = National Institutes of Health; USPHS = U.S. Public Health Service
### Appendix 2. Criteria for Testing for HIV Infection

<table>
<thead>
<tr>
<th>Condition</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unexplained signs/symptoms compatible with acute HIV infection</td>
<td>Including, but not limited to: fever, adenopathy, pharyngitis, rash, myalgias, diarrhea and headache.</td>
</tr>
<tr>
<td>Signs/symptoms of HIV-related condition</td>
<td>Including, but not limited to: <em>candida</em>, herpes zoster, oral hairy leukoplakia, severe seborrhea, unexplained lymphadenopathy, and opportunistic infections.</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Testing is recommended for all pregnant women as early as possible during pregnancy. Current antiretroviral therapy and obstetrical interventions markedly reduce the risk of transmitting HIV from infected mothers to their infants.</td>
</tr>
<tr>
<td>Recent exposures to HIV</td>
<td>Follow-up HIV-antibody testing should be performed at the following intervals after the exposure date: 6 weeks, 12 weeks, and 6 months (and 12 months for those who become infected with HCV after exposure to a source coinfected with HIV and HCV).</td>
</tr>
<tr>
<td>Active tuberculosis</td>
<td>HIV infection is a potent risk factor for developing active tuberculosis.</td>
</tr>
<tr>
<td>Otherwise clinically indicated</td>
<td>On a case-by-case basis.</td>
</tr>
</tbody>
</table>

**Mandatory** test sentenced (6 months or more) inmates with the following risk factors:

- Injected illegal drugs and shared equipment
- (For males) sex with another man
- Had unprotected intercourse with a person with known or suspected HIV infection
- History of gonorrhea or syphilis
- Had unprotected intercourse with more than one sex partner
- From a high-risk country (sub-Saharan Africa or West Africa).
- Received blood products between 1977 and May 1985
- Hemophilia
- Percutaneous exposure to blood
- Positive tuberculin skin test

**Offer voluntary testing to all sentenced inmates at the time of incarceration:**

**Opt-out voluntary testing** is offered to all designated inmates after arrival to the designated institution. Many persons with HIV infection are asymptomatic and are unaware of their infection; therefore, consistent with guidelines from the Centers for Disease Control and Prevention and the issued memorandum from the BOP Medical Director, all sentenced inmates should universally be offered HIV testing at the time of incarceration.

Voluntary testing via an Inmate Request to Staff Member (BP-S148) form is also available to all inmates regardless of sentencing or duration of stay.
### Appendix 3. Correlation of Complications with CD4+ T Cell Count*

<table>
<thead>
<tr>
<th>CD4+ T cells/mm³</th>
<th>Infectious Complications</th>
<th>Non-Infectious Complications**</th>
</tr>
</thead>
</table>
| >500             | • Acute retroviral syndrome  
   • Candidal vaginitis       | • Persistent generalized lymphadenopathy (PGL)  
   • Guillain-Barré syndrome  
   • Myopathy                | • Cervical intraepithelial neoplasia  
   • Anemia                   | • Cervical cancer  
   • Mononeuronal multiplex   | • B-cell lymphoma  
   • Mononeuronal multiplex   | • Anemia  
   • Bone marrow suppression  | • Lymphocytic interstitial pneumonitis |
| 200–500           | • Pneumococcal and other bacterial pneumonia  
   • Pulmonary tuberculosis  
   • Herpes zoster           | • Pneumocystis pneumonia  
   • Oropharyngeal candidiasis (thruph)  
   • Cryptosporidiosis, self-limited  
   • Kaposi’s sarcoma         | • Wasting  
   • Oral hairy leukoplaikia  | • Peripheral neuropathy  
                           | • HIV-associated dementia  
                           | • Cardiomyopathy  
                           | • Vacuolar myelopathy  
                           | • Progressive polyradiculopathy  
                           | • Non-Hodgkin’s lymphoma  
| <200              | • Pneumocystis pneumonia  
   • Disseminated histoplasmosis  
   • Coccidioidomycosis  
   • Miliary/extrapulmonary TB  
   • Progressive multifocal leukoencephalopathy (PML) | • Wasting  
   • Peripheral neuropathy  
   • HIV-associated dementia  
   • Cardiomyopathy  
   • Vacuolar myelopathy  | • Progressive polyradiculopathy  
   • Non-Hodgkin’s lymphoma  |
| <100              | • Disseminated herpes simplex  
   • Toxoplasmosis            | • Wasting  
   • Cryptococcosis           | • Peripheral neuropathy  
   • Cryptosporidiosis, chronic  
   • Microsporidiosis         | • HIV-associated dementia  
   • Candidal esophagitis     | • Cardiomyopathy  
                           | • Vacuolar myelopathy  
                           | • Progressive polyradiculopathy  
                           | • Non-Hodgkin’s lymphoma  |
| <50               | • Disseminated cytomegalovirus (CMV)  
   • Disseminated *Mycobacterium avium* complex | • Wasting  
   • Peripheral neuropathy  
   • HIV-associated dementia  
   • Cardiomyopathy  
   • Vacuolar myelopathy  | • Progressive polyradiculopathy  
   • Non-Hodgkin’s lymphoma  |

* Most complications occur with increasing frequency at lower CD4+ T cell counts.

** Some conditions listed as non-infectious are probably associated with transmissible microbes. Examples include lymphoma (Epstein-Barr virus [EBV]) and cervical cancer (human papilloma virus [HPV]).

### Appendix 4. Baseline and Periodic Medical/Laboratory Evaluations for Inmates with HIV Infection

<table>
<thead>
<tr>
<th>History/Physical:</th>
<th>Baseline</th>
<th>Periodic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundoscopic exam</td>
<td>• RPR/FTA</td>
<td>• CBC, platelets, differential (q 3 to 6 months while on antiretroviral therapy)</td>
</tr>
<tr>
<td>Pap smear (women)</td>
<td>• TST/TB symptom review</td>
<td>• Periodic RPR (as clinically indicated)</td>
</tr>
<tr>
<td>CD4+T cell count (absolute and %)</td>
<td>• Chest radiograph</td>
<td>• Pap smear within 6 months; then annually (refer to gynecologist as indicated for colposcopy)</td>
</tr>
<tr>
<td>HIV RNA (viral load)</td>
<td>• Toxoplasma gondii IgG</td>
<td>• Influenza vaccine annually</td>
</tr>
<tr>
<td>Resistance testing</td>
<td>• Hepatitis A, B, &amp; C serologies</td>
<td>Other laboratory tests as indicated</td>
</tr>
<tr>
<td>CBC, platelets, differential</td>
<td>• Influenza vaccine</td>
<td>► Annual TST ► G-6-PD</td>
</tr>
<tr>
<td>Serum chemistries, transaminase levels, BUN, creatinine, urinalysis</td>
<td>• Pneumococcal vaccine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Hepatitis B vaccine (if at risk)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fasting lipid profile &amp; glucose</td>
<td></td>
</tr>
</tbody>
</table>

### Laboratory Monitoring Schedule for Patients Prior to and After Initiation of Antiretroviral Therapy

(Based on February 14, 2013 DHHS Guidelines)

<table>
<thead>
<tr>
<th></th>
<th>Entry into care</th>
<th>Follow-up before ART</th>
<th>ART indication of modification</th>
<th>2-8 weeks post-ART initiation or modification</th>
<th>Every 3-6 months</th>
<th>Every 6 months</th>
<th>Every 12 months</th>
<th>Treatment failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Serology</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4 Count</td>
<td>X</td>
<td>q 3-6 mo.</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Viral Load</td>
<td>X</td>
<td>q 3-6 mo.</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Resistance Testing</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-B 5701</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>If considering CCR5 ant.</td>
</tr>
<tr>
<td>Tropism Testing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hep B Serology</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic Chemistry</td>
<td>X</td>
<td>q 6-12 mo.</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT, AST, T. bill</td>
<td>X</td>
<td>q 6-12 mo.</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBC w/ Differential</td>
<td>X</td>
<td>q 3-6 mo.</td>
<td>X</td>
<td>if on zidovudine</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid Profile</td>
<td>X</td>
<td>if normal, annually</td>
<td>X</td>
<td>consider 4-8 wk. w/ new ART</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting Glucose or Hemoglobin A1C</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UA</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coagulation Testing</td>
<td></td>
<td>As needed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Preprocedural need for invasive dental procedures for high-risk HIV patients.
## Appendix 5. HIV Classification System

<table>
<thead>
<tr>
<th>CD4+ T cells/mm³</th>
<th>A - Asymptomatic</th>
<th>B - Symptomatic Disease</th>
<th>C - AIDS Indicator Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥500</td>
<td>A1</td>
<td>B1</td>
<td>C1*</td>
</tr>
<tr>
<td>200–499</td>
<td>A2</td>
<td>B2</td>
<td>C2*</td>
</tr>
<tr>
<td>&lt;200</td>
<td>A3*</td>
<td>B3*</td>
<td>C3*</td>
</tr>
</tbody>
</table>

* 1993 CDC Classification System: Categories A3, B3, C1, C2, and C3 are AIDS reportable.

### A - Asymptomatic
- Acute (primary) HIV infection
- Persistent generalized lymphadenopathy (PGL)

### B - Symptomatic Disease
Symptomatic conditions that are attributed to HIV infection, or conditions that have a clinical course complicated by HIV. Conditions include, but are not limited to:
- Bacillary angiomatosis
- Oral candidiasis
- Vulvovaginal candidiasis: persistent (>1 month or poorly responsive to therapy)
- Cervical dysplasia (moderate–severe or CIS)
- Idiopathic thrombocytic purpura (ITP)
- Oral hairy leukoplakia
- Listerial disease
- Herpes zoster (involving more than 1 dermatome or 2 separate episodes)

### C - AIDS Indicator Conditions
- Candidiasis: esophagus, trachea, bronchi or lungs
- Cervical cancer (invasive)
- Coccioidiodymcosis (extrapulmonary)
- Cryptococcosis (extrapulmonary)
- Cryptosporidiosis with diarrhea (>1 month)
- Cytomegalovirus of any organ other than liver, spleen, or lymph nodes; eye
- Herpes simplex with genital/oral ulcers >1 month, or bronchitis, pneumonitis, esophagitis
- Histoplasmosis (extrapulmonary)
- HIV-associated dementia
- HIV-associated wasting syndrome
- Isoporosis with diarrhea (>1 month)
- Kaposi’s sarcoma in patient under 60 years
- Lymphoma (Burkitt’s, immunoblastic, or primary CNS)
- Mycobacterium avium (disseminated)
- M. tuberculosis (pulmonary or extrapulmonary)
- Pneumocystis pneumonia (PCP)
- Pneumonia (bacterial, recurrent): ≥ 2 episodes within 12 months
- Progressive multifocal leukoencephalopathy
- Salmonella septicemia (nontyphoid), recurrent
- Toxoplasmosis of internal organ

**Note:** Category B conditions take precedence over those in Category A; and Category C conditions take precedence over those in Category B. For classification purposes, the lowest accurate CD4+ T cell count or percentage (not necessarily the most recent) should be used.
## Appendix 6. Prophylaxis for HIV-Related Opportunistic Infections

<table>
<thead>
<tr>
<th>Drug/Dosages</th>
<th>Toxicities</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pneumocystis Pneumonia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INDICATIONS:</strong></td>
<td>CD4+ T cells &lt;200/mm³ or oropharyngeal candidiasis. Can stop primary and secondary PCP prophylaxis if CD4+ T cells &gt;200/mm³ for 3 months.</td>
<td></td>
</tr>
<tr>
<td><strong>FIRST CHOICE:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TMP-SMX (Bactrim, Septra)</td>
<td>rash, fever, nausea, leukopenia, hepatitis</td>
<td>● Prevents toxoplasmosis and bacterial infections.</td>
</tr>
<tr>
<td>1 DS PO daily or 1 SS daily</td>
<td></td>
<td>● Use 1 DS/day if toxo IgG+.</td>
</tr>
<tr>
<td><strong>ALTERNATIVES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dapsone</td>
<td>hemolysis, methemoglobinemia</td>
<td>● Screening for G6-PD deficiency recommended in high-risk patients.</td>
</tr>
<tr>
<td>100 mg/day or 50 mg BID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pentamidine</td>
<td>bronchospasm/cough (responds to bronchodilator bx)</td>
<td>● Obtain screening chest x-ray for TB.</td>
</tr>
<tr>
<td>300 mg q month aerosolized</td>
<td></td>
<td>● Administer pentamidine by Respigrad II nebulizer.</td>
</tr>
<tr>
<td>Atovaquone</td>
<td>rash, GI intolerance</td>
<td>● Must be taken with meals for absorption.</td>
</tr>
<tr>
<td>1500mg PO daily</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Toxoplasmosis**

**INDICATION:** Toxo IgG+ and CD4+ T cells <100 cells/mm³. Can stop primary toxoplasmosis prophylaxis if CD4+ T cell count is >200/mm³ for >3 months; can stop secondary prophylaxis if CD4+ T cell count is >200/mm³ and asymptomatic for >6 months.

**FIRST CHOICE:**

<table>
<thead>
<tr>
<th>Drug/Dosages</th>
<th>Toxicities</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMP-SMX (Bactrim, Septra)</td>
<td>rash, fever, nausea, leukopenia, hepatitis</td>
<td>● Repeat toxo IgG if titer was negative when CD4+ T cells were &lt;100/mm³.</td>
</tr>
<tr>
<td>1 DS/day</td>
<td></td>
<td>● Monitor for anemia/leukopenia; CBC q 3–4 months.</td>
</tr>
<tr>
<td><strong>ALTERNATIVE:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dapsone 50mg/day &amp; Pyrimethamine 50mg/wk &amp; Leucovorin 25mg/wk</td>
<td>hemolysis, anemia</td>
<td>● Monitor for anemia/leukopenia; CBC q 3–4 months.</td>
</tr>
</tbody>
</table>

**Mycobacterium avium**

**INDICATION:** CD4+ T cell count <50 cells/mm³. Can stop primary prophylaxis if completed ≥12 months of therapy and no sx of MAC and CD4+ count >100 cells/mm³ for ≥6 months.

**FIRST CHOICES:**

<table>
<thead>
<tr>
<th>Drug/Dosages</th>
<th>Toxicities</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin</td>
<td>nausea/vomiting</td>
<td></td>
</tr>
<tr>
<td>1200 mg/week</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>nausea/vomiting</td>
<td></td>
</tr>
<tr>
<td>500 mg BID</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ALTERNATIVE:**

<table>
<thead>
<tr>
<th>Drug/Dosages</th>
<th>Toxicities</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rifabutin</td>
<td>uveitis, arthralgias, hepatitis</td>
<td>● Uveitis when given with fluconazole; creates rifampin resistance; review drug interactions.</td>
</tr>
</tbody>
</table>
Appendix 7. DHHS Antiretroviral Guidelines: Rating Scheme and Acronyms

Below are the rating scheme and the acronyms used in Appendices 8–10 of these guidelines.

<table>
<thead>
<tr>
<th>Strength of Recommendation</th>
<th>Quality of Evidence for Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A: Strong recommendation for the statement</td>
<td>I: One or more randomized trials with clinical outcomes and/or validated laboratory endpoints</td>
</tr>
<tr>
<td>B: Moderate recommendation for the statement</td>
<td>II: One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes</td>
</tr>
<tr>
<td>C: Optional recommendation for the statement</td>
<td>III: Expert opinion</td>
</tr>
</tbody>
</table>

### Acronyms

#### Drug Classes

<table>
<thead>
<tr>
<th>EI</th>
<th>entry inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRTI</td>
<td>nucleoside reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>INSTI</td>
<td>integrase strand transfer inhibitor</td>
</tr>
<tr>
<td>PI</td>
<td>protease inhibitor</td>
</tr>
<tr>
<td>NNRTI</td>
<td>non-nucleoside reverse transcriptase inhibitor</td>
</tr>
</tbody>
</table>

#### Antiretroviral Drugs

| 3TC | lamivudine |
| ABC | abacavir |
| ATV | atazanavir |
| ATV/r | atazanavir + ritonavir |
| d4T | stavudine |
| ddC | zalcitabine |
| dDI | didanosine |
| DLV | delavirdine |
| DRV | darunavir |
| DRV/r | darunavir + ritonavir |
| EFV | efavirenz |
| EVG/COBI/TDF/FTC | elvitegravir + cobicistat + tenofovir + emtricitabine |
| ETR | etravirine |
| FPV | fosamprenavir |
| SQV/r | saquinavir + ritonavir |
| TDF | tenofovir |

#### Other

| ALT | alanine aminotransferase |
| GI | gastrointestinal |
| ARV | antiretroviral |
| HBV | hepatitis B virus |
| AST | aspartate aminotransferase |
| HCV | hepatitis C virus |
| DM | diabetes mellitus |

Appendix 8. Initiating Antiretroviral Therapy in Treatment-Naïve Patients

<table>
<thead>
<tr>
<th>General Recommendations for Initiating Antiretroviral Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Ratings for the following recommendations are in parentheses. See Appendix 7 for the rating scheme.)</td>
</tr>
</tbody>
</table>

Based on the cumulative weight of evidence described above, the Panel recommends that:

- Antiretroviral therapy (ART) is recommended for all HIV-infected individuals to reduce the risk of disease progression. The strength and evidence for this recommendation vary by pretreatment CD4 cell count:
  - CD4 count <350 cells/mm$^3$ (AI)
  - CD4 count 350–500 cells/mm$^3$ (AII)
  - CD4 count ≥500 cells/mm$^3$ (AIII)

- ART also is recommended for HIV-infected individuals for the prevention of transmission of HIV.
  - Perinatal transmission (AI)
  - Heterosexual transmission (AI)
  - Other transmission risk groups (AIII)

- Patients starting ART should be willing and able to commit to treatment and understand the benefits and risks of therapy and the importance of adherence (AIII). Patients may choose to postpone therapy, and providers, on a case-by-case basis, may elect to defer therapy on the basis of clinical and/or psychosocial factors.

Appendix 9. Preferred Treatment Regimens for Antiretroviral-Naïve Patients

<table>
<thead>
<tr>
<th>Recommended Treatment Regimens for Antiretroviral-Naïve Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regimens should be individualized, based on the advantages and disadvantages of each combination. Considerations should include: pill burden, dosing frequency, toxicities, drug-drug interaction potential, co-morbid conditions, and level of plasma HIV-RNA. Clinicians should refer to the DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents referenced below to review the pros and cons of the different components of a regimen, as well as the adverse effects and dosages of individual antiretroviral agents. Ratings for the DHHS Panel’s recommendations are in parentheses. See Appendix 7 for the rating scheme and a list of the acronyms used. See the What to Start section for the BOP recommended dosages for each regimen.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Preferred Regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>The following regimens are preferred because they have optimal and durable efficacy, a favorable tolerability and toxicity profile, and ease of use. Except for the recommendation for pregnant women, the preferred regimens are arranged by duration of clinical experience.</td>
</tr>
</tbody>
</table>

**NNRTI-BASED REGIMEN**
- EFV/TDF/FTC (AI)

**PI-BASED REGIMENS (in alphabetical order)**
- ATV/r + TDF/FTC (AI)
- DRV/r (once daily) + TDF/FTC (AI)

**INSTI-BASED REGIMEN**
- RAL + TDF/FTC (AI)

**PREFERRED REGIMEN FOR PREGNANT WOMEN**

**Comments:**
- EFV should not be used during the first trimester of pregnancy or in women trying to conceive or not using effective and consistent contraception.
- ATV/r should not be used in patients who require >20 mg omeprazole equivalent per day. Refer to Table 15a of the DHHS Guidelines (referenced below) for dosing recommendations regarding interactions between ATV/r and acid-lowering agents.

**Alternative Regimens**

The following regimens are effective and tolerable, but have potential disadvantages compared to the preferred regimens. An alternative regimen may be the preferred regimen for some patients.

**NNRTI-BASED REGIMENS (in alphabetical order)**
- EFV + ABC/3TC (BI)
- RPV/TDF/FTC (BI)

**PI-BASED REGIMENS (in alphabetical order)**
- ATV/r + ABC/3TC (BI)
- DRV/r + ABC/3TC (BII)
- FPV/r (once or twice daily) + either ABC/3TC or TDF/FTC (BI)
- LPV/r (once or twice daily) + either ABC/3TC or TDF/FTC (BI)

**INSTI-BASED REGIMEN**
- EVG/COBI + TDF + FTC (BI)

**Comments:**
- RVP
  - RPV is not recommended in patients with pretreatment HIV RNA >100,000 copies/mL.
  - Higher rate of virologic failures reported in patients with pre-ART CD4 count <200 cells/mm³ who are treated with RPV + 2NRTI
- Use of PPIs with RPV is contraindicated.

- ABC
  - ABC should not be used in patients who test positive for HLA-B*5701.
  - Use ABC with caution in patients with high risk of cardiovascular disease or with pretreatment HIV RNA >100,000 copies/mL.

- EVG/COBI/TDF/FTC
  - Should not be started in patients with CrCl <70ml/min or used with nephrotoxic drugs.

### Appendix 10. Antiretroviral Drugs and Components NOT Recommended

#### Do Not Offer at Any Time

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monotherapy with NRTI</td>
<td>Rapid development of resistance</td>
</tr>
<tr>
<td>Dual therapy NRTI regimens</td>
<td>Rapid development of resistance</td>
</tr>
<tr>
<td>Triple-NRTI regimens except for ABC/ZDV/3TC (BI) or possibly TDF + ZDV/3TC</td>
<td>High rate of early virologic nonresponse</td>
</tr>
<tr>
<td>Atazanavir + indinavir</td>
<td>Potential additive hyperbilirubinema</td>
</tr>
<tr>
<td>Didanosine + stavudine</td>
<td>High incidence of toxicities</td>
</tr>
<tr>
<td>Didanosine + tenofovir</td>
<td>Potential for immunologic nonresponse</td>
</tr>
<tr>
<td>Emtricitabine + lamivudine</td>
<td>No potential benefit</td>
</tr>
<tr>
<td>Stavudine + zidovudine</td>
<td>Antagonistic effect on HIV-1</td>
</tr>
<tr>
<td>2-NNRTI combinations</td>
<td>Higher incidence of clinical adverse events and induced metabolism</td>
</tr>
<tr>
<td>Evavirenz (in first trimester of pregnancy or in women with significant child-bearing potential)</td>
<td>Teratogenic in nonhuman primates</td>
</tr>
<tr>
<td>Nevirapine (initiation with CD4+ T cell counts &gt;250 cells/mm³ for women or &gt;400 cells/mm³ for men)</td>
<td>High incidence of symptomatic hepatotoxicity</td>
</tr>
<tr>
<td>Etravirine + unboosted PI</td>
<td>ETR may induce metabolism of these PIs</td>
</tr>
<tr>
<td>Etravirine + ritonavir-boosted atazanavir or fosamprenavir</td>
<td>ETR may alter the concentrations of these PIs</td>
</tr>
<tr>
<td>Etravirine + ritonavir-boosted tipranavir</td>
<td>ETR concentration may be significantly reduced</td>
</tr>
<tr>
<td>Unboosted darunavir, saquinavir, or tipranavir</td>
<td>Inadequate bioavailability</td>
</tr>
</tbody>
</table>

→ Review DHHS Guidelines (referenced below) for possible exceptions to the above recommendations.

#### Do Not Offer as Initial Therapy

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC/3TC/ZDV (coformulated) as triple-NRTI combination regimen</td>
<td>Inferior virologic efficacy</td>
</tr>
<tr>
<td>ABC + 3TC + ZDV + TDF as quadruple-NRTI combination</td>
<td>Inferior virologic efficacy</td>
</tr>
<tr>
<td>ABC + ddl or TDF</td>
<td>Insufficient data in ART-naïve patients</td>
</tr>
<tr>
<td>DRV (unboosted)</td>
<td>Use without RTV has not been studied</td>
</tr>
<tr>
<td>DLV</td>
<td>Inferior virologic efficacy</td>
</tr>
<tr>
<td>ddl + 3TC(or FTC)</td>
<td>Inferior virologic efficacy</td>
</tr>
<tr>
<td>ddl + TDF</td>
<td>High rate of early virologic failure; rapid selection of resistant mutations; potential for immunologic nonresponse</td>
</tr>
<tr>
<td>EVG/COBI/TDF/FTC + other ARV drugs</td>
<td>Potential for drug-drug interactions</td>
</tr>
<tr>
<td>T-20</td>
<td>No trial experience in ART-naïve</td>
</tr>
</tbody>
</table>

(Table continues on next page.)
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETR</td>
<td>Insufficient data in ART-naïve patients</td>
</tr>
<tr>
<td>FPV (unboosted)</td>
<td>Less potent than RTV-boosted</td>
</tr>
<tr>
<td>IDV (unboosted)</td>
<td>Inconvenient dosing</td>
</tr>
<tr>
<td>IDV (RTV-boosted)</td>
<td>High incidence of nephrolithiasis</td>
</tr>
<tr>
<td>NFV</td>
<td>Inferior virologic efficacy</td>
</tr>
<tr>
<td>RTV as sole PI</td>
<td>Gastrointestinal intolerance</td>
</tr>
<tr>
<td>SQV (unboosted)</td>
<td>Inferior virologic efficacy</td>
</tr>
<tr>
<td>d4T + 3TC</td>
<td>Significant toxicities including lipoatrophy; peripheral neuropathy; and hyperlactatemia, including symptomatic and life-threatening lactic acidosis, hepatic steatosis, and pancreatitis</td>
</tr>
<tr>
<td>TPV (ritonavir-boosted)</td>
<td>Inferior virologic efficacy</td>
</tr>
</tbody>
</table>

**Note:** Acronyms are defined in Appendix 7.

## Appendix 11. Procedure for Pap Smears

<table>
<thead>
<tr>
<th>Pap Smear Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>The cervix is scraped circumflexually with an Ayer spatula or a curved brush; a sample from the posterior fornix or the vaginal pool may also be included. The endocervical sample is taken with a saline-moistened, cotton-tipped applicator or a straight ectocervical brush, which is rolled on a slide and immediately fixed in ethyl ether plus 95% ethyl alcohol, or in 95% ethyl alcohol alone. The yield is 7-fold higher with the brush specimen.</td>
</tr>
</tbody>
</table>

**Important points for obtaining an adequate sample are below:**

- Collect the Pap smear prior to the bimanual exam, to avoid contaminating the sample with lubricant.
- Obtain the Pap before testing for sexually transmitted diseases.
- If a large amount of vaginal discharge is present, carefully remove it with a large swab before collecting the Pap smear.
- Obtain the ectocervical sample before obtaining the endocervical sample.
- Small amounts of blood will not interfere with cytologic sampling; defer Pap if bleeding is heavy.
- Collected material should be applied uniformly to the slide, without clumping, and should be fixed immediately to avoid air-drying.
- If spray fixatives are used, the spray should be held at least 10 inches away from the slide to prevent disruption of cells by the propellant.
- When performing speculum examination, if an ulcerative or exophytic lesion is detected and is suspicious for cancer, a referral for possible biopsy is warranted.

**Note:** New liquid-based collection and thin layer processing methods decrease the frequency of inadequate smears and provide more sensitive and specific results.

## Appendix 12. Recommendations for Using Drug-Resistance Assays

<table>
<thead>
<tr>
<th>Clinical Setting/Recommendation</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Note:</strong> Drug resistance assay is not usually recommended more than 4 weeks after discontinuation of ARV drugs and in patients with a plasma viral load &lt;500 copies/ml.</td>
<td></td>
</tr>
<tr>
<td><strong>In acute HIV infection:</strong></td>
<td></td>
</tr>
<tr>
<td>Drug-resistance testing is recommended regardless of whether antiretroviral therapy (ART) is initiated immediately or deferred. A genotypic assay is generally preferred.</td>
<td>If ART is initiated immediately, drug-resistance testing can determine whether drug-resistant virus was transmitted. Test results will help in the design of initial regimens or to modify or change regimens if results are obtained after treatment initiation. Genotypic testing is preferred to phenotypic testing because of lower cost, faster turnaround time, and greater sensitivity for detecting mixtures of wild-type and resistant virus.</td>
</tr>
<tr>
<td><strong>In ART-naive patients with chronic HIV infection:</strong></td>
<td></td>
</tr>
<tr>
<td>Drug-resistance testing is recommended at entry into HIV care, regardless of whether therapy is initiated immediately or deferred. A genotypic assay is generally preferred.</td>
<td>Transmitted HIV with baseline resistance to at least one drug is seen in 6–16% of patients, and suboptimal virologic responses may be seen in patients with baseline resistant mutations. Some drug resistance mutations can remain detectable for years in untreated, chronically infected patients. Genotypic testing is preferred to phenotypic testing because of lower cost, faster turnaround time, and greater sensitivity for detecting mixtures of wild-type and resistant virus. Standard genotypic drug-resistance assays test only for mutations in the RT and PR genes.</td>
</tr>
<tr>
<td>• If an INSTI is considered for an ART-naive patient and transmitted INSTI resistance is a concern, providers may supplement standard resistance testing with a specific INSTI genotypic resistance assay.</td>
<td></td>
</tr>
<tr>
<td>• If use of a CCR5 antagonist is being considered, a co-receptor tropism assay should be performed.</td>
<td></td>
</tr>
<tr>
<td><strong>In patients with virologic failure:</strong></td>
<td></td>
</tr>
<tr>
<td>Drug-resistance testing is recommended in patients on combination ART with HIV RNA levels &gt;1,000 copies/mL. A standard genotypic resistance assay is generally preferred for patients experiencing virologic failure on their first or second regimens.</td>
<td>Testing can help determine the role of resistance in drug failure and maximize the clinician's ability to select active drugs for the new regimen. Drug-resistance testing should be performed while the patient is taking prescribed ARV drugs or, if not possible, within 4 weeks after discontinuing therapy. Phenotypic testing can provide additional useful information in patients with complex drug-resistance mutation patterns, particularly to PIs.</td>
</tr>
<tr>
<td>• In patients failing INSTI-based regimens, genotypic testing for INSTI resistance should be performed to determine whether to include drugs from this class in subsequent regimens.</td>
<td></td>
</tr>
<tr>
<td>• If use of a CCR5 antagonist is being considered, a co-receptor tropism assay should be performed.</td>
<td></td>
</tr>
<tr>
<td>• Addition of phenotypic assay to genotypic assay is generally preferred in patients with known or suspected complex drug resistance patterns, particularly to protease inhibitors (PIs).</td>
<td></td>
</tr>
</tbody>
</table>

→ Drug-resistance assay is recommended in patients with suboptimal suppression of viral load after initiation of ART.

**Note:** Acronyms are defined in Appendix 7